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Abstract 
Background: Hypertension-induced arterial stiffness is associated with high risks of 
morbidity and mortality. The sympathetic nervous system plays an important role in the 
control of cardiovascular function through beta-adrenoceptors (β-AR). The involvement 
of β-AR in the control of arterial stiffness in a state of hypertension and normotension 
was examined. Methods: Pulse wave velocity (PWV) was assessed within a narrow 
range of blood pressures in isoflurane-anaesthetized 13-14-week-old male spontaneously 
hypertensive (SH) and Wistar-Kyoto (WKY) rats. Results: Baseline PWV was higher in 
SH (9.2±0.9 m/s) compared to WKY rats (6.7±0.4 m/s).  The stimulation of β2- but not 
β3-AR reduced PWV in SH rats despite comparable reductions in blood pressure. Sodium 
nitroprusside infusions initiated a dose-dependent reduction of PWV in SH rats. 
Conclusion: The evidence suggests that a reduction in central vascular tone may play a 
key role in decreasing elevated PWV independently from reduction in blood pressure in a 
state of hypertension. 
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1. Introduction  
1.1 Circulatory system  
Blood vessels deliver oxygen and nutrients to organs and tissues in the body, as well 
as enable the removal of metabolic waste and CO2 from cells. Systemic arteries carry 
oxygenated blood coming from the heart and circulate it throughout the body, while 
systemic veins return deoxygenated blood to the heart. The blood can then be pumped to 
the pulmonary vasculature where it will be oxygenated. In the pulmonary vasculature, the 
arteries carry deoxygenated blood to the lungs where it can be oxygenated, and the veins 
return oxygenated blood to the heart, from the pulmonary vasculature. The systemic 
artery with the largest diameter, the aorta, originates from the left cardiac ventricle. It 
then branches into small arteries, and subsequently into arterioles. Arterioles branch into 
capillaries, which allow the exchange of oxygen and nutrients with tissues. Small arteries 
such as arterioles are often referred to as resistance vessels because they have the greatest 
sectioned area, along with the greatest fall in blood pressure compared to other arteries, 
which suggests that they are the segment of the circulation with the greatest vascular 
resistance. Resistance vessels alter the lumen diameter by vasoconstriction or 
vasodilation, which increases and decreases vascular resistance, respectively (Marieb and 
Hoehn, 2013). 
Blood vessels are composed of three layers; the tunica intima, the tunica media, and 
the tunica externa (tunica adventitia) (Figure 1). The tunica intima is the inner lining of 
blood vessels, and is composed of a single layer of endothelial cells and the underlying 
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subendothelial space that play many important roles in the vasculature, including the 
secretion of dilatory factors such as nitric oxide (NO). Capillaries are composed of 
endothelial cells, and are unique blood vessels, as they lack the tunica media and externa. 
Capillaries are known as the major exchange site for oxygen, nutrients, and waste. The 
tunica media is composed chiefly of elastin, an elastic fiber, as well as vascular smooth 
muscle cells (VSMCs). Two essential functions of VSMCs include contraction and 
dilation. The associated alteration in vascular tone leads to an increased or decreased 
lumen diameter, which subsequently alters resistance to blood flow as well as blood 
pressure. Arteries are mainly composed of VSMCs, and also have a high elastin content, 
which increases vascular elasticity. Elastin can be found in the tunica externa and the 
tunica media, as well as the border between the intima and media (internal elastic lamina) 
and between the tunica media and externa (external elastic lamina). However, it is 
predominantly present in the tunica media, between VSMCs (Marieb and Hoehn, 2013). 
Finally, the outer lining, the tunica externa, is composed of connective tissue, which 
serves to reinforce the tissue and connect it to neighboring tissues (Marieb and Hoehn, 
2013). The extracellular matrix (ECM) of this layer of tissue is composed of collagen 
(mostly type I and III) (Shekhonin et al., 1987), which is a rigid fiber, as well as nerve 
fibers and lymphatic vessels (Marieb and Hoehn, 2013).
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Figure 1. Schematic of rat abdominal aorta using transmitted light imaging, with a 20X 
objective and 1.9X magnification. The image shows the three layers of the arterial wall; 
the tunica intima, tunica media and the tunica externa. 
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1.2 Hypertension 
Hypertension is defined as chronic high intravascular arterial pressure. Hypertension 
has traditionally been diagnosed when blood pressure reaches ≥140/90 mmHg 
(Chobanian et al., 2003). Blood pressure classifications can be found in Table 1. 
However, more complicated criteria have been developed, such as taking multiple blood 
pressure readings in the same clinical visit (among other measures for diagnosis) (Leung 
et al., 2017). Hypertension is the most common ailment in clinical settings (Chobanian et 
al., 2003). Essential (or primary) hypertension is a subset of hypertension that is 
diagnosed when the hypertension has no obvious cause. Secondary hypertension, which 
is less common, occurs due to other ailments such as renal occlusive disease or 
hyperthyroidism (Marieb and Hoehn, 2013). Hypertension is one of the leading causes of 
stroke, heart failure, renal failure, and myocardial infarction, which can contribute to a 
higher risk of mortality (James et al., 2014). Chronic high systolic pressure and reduced 
diastolic blood pressure often occur in subjects with increased central vascular stiffness 
(Mackenzie et al., 2002). High systolic pressure increases cardiac metabolism and 
therefore requires more blood flow to the heart, while reduced diastolic pressure 
(produced by a reduction in vascular resistance) results in decreased perfusion pressure in 
the coronary arteries. Eventually, this reduces the delivery of oxygen to the myocardium, 
which may result in heart failure (Mackenzie et al., 2002).  
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Table 1. Hypertension classification according to Chobanian and colleagues (2003) 
Blood pressure 
classification Systolic pressure (mmHg) Diastolic pressure (mmHg) 
Normal <120 <80 
Pre-hypertension 120-139 80-89 
Hypertension 
Stage 1 ≥140 ≥ 90 
Stage 2 ≥ 160 ≥ 100 
 
1.2.1 The spontaneously hypertensive (SH) rat – a widely used animal model of 
hypertension  
The spontaneously hypertensive (SH) rat was developed by selective breeding to 
study the pathophysiology of hypertension (Okamoto and Aoki, 1963). Male SH rats 
develop hypertension with a systolic pressure of approximately 154 ± 5 mmHg by 13 to 
14 weeks of age, independently from environmental stimuli (data from the current 
investigation). The systolic blood pressure of the normotensive Wistar-Kyoto (WKY) rat 
is approximately 106 ± 4 mmHg at 13 to 14 weeks of age (data from the current 
investigation). Transplantation of both kidneys of an SH rat to their normotensive 
counterpart, the Wistar-Kyoto (WKY) rat, has been shown to induce hypertension in the 
WKY rat. The transplantation of both kidneys from a WKY to an SH rat, on the other 
hand, resulted in normal blood pressure in the SH rat. Therefore, it has been suggested 
that hypertension in the SH rat originates from the kidneys (Rettig, 1993). The SH rat is a 
suitable model for experiments pertaining to high intravascular pressure, since the 
pathophysiology is very similar to that of humans (Pinterova et al., 2011). For example, 
left ventricular hypertrophy is one of the complications of chronic hypertension in SH 
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rats (Institute of Laboratory Animal Resources, 1976). Arterial stiffness is another 
common complication of hypertension reported in SH rats (Sehgel et al., 2013), as well as 
in humans (Zieman et al., 2005). The manifestation of increased arterial stiffness can also 
occur independently from high blood pressure. 
1.3 Arterial Stiffness 
Arterial stiffness can be defined as a reduction in the elasticity of arteries. Increased 
aortic stiffness is often associated with hypertension, and increased rates of 
cardiovascular morbidity and mortality (Zieman et al., 2005). In normal physiological 
conditions, the aorta serves as a conduit vessel and a pressure buffer; since central arteries 
have high elastin content, they distend when blood pressures increase during systole, and 
recoil during diastole. This is known as the Windkessel effect, which allows dampening 
of the pulse pressure, as well as continuous blood flow and perfusion of smaller blood 
vessels and capillaries (Belz, 1995). When arteries become stiffer, their ability to distend 
is diminished, as well as their ability to dampen pulse pressure, which contributes to 
larger pulse pressures in arterial stiffness (Belz, 1995). There is increasing evidence that 
the assessment of arterial stiffness can predict cardiovascular risk (Zieman et al., 2005; 
Boutouyrie et al., 2014). 
1.3.1 Assessment of arterial stiffness 
The mechanical and dynamic properties of blood vessels are often described in 
various ways. Viscoelasticity describes the time-dependent mechanical properties of 
blood vessels; once they are subjected to a deformation, there is a delay to reach the 
appropriate shape relative to the deformation (visco-), and to return to its original shape 
once the stress is removed (-elasticity). Pressure, diameter, and wall thickness can be 
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measured to quantify these dynamic changes in vivo (Milnor, 1989) and contribute to 
defining the mechanical properties of arteries, by using indices of stiffness such as pulse 
pressure and pulse wave velocity (PWV).  
Pulse pressure is the difference between systolic and diastolic pressure. As age 
increases, systolic blood pressure increases (Franklin et al., 1997), and diastolic blood 
pressure tends to decrease (Mackenzie et al., 2002). This creates a widening of the pulse 
pressure with increasing age. Pulse pressure seems to be a predictor of cardiovascular 
health and disease. It has been suggested that pulse pressure is a better predictor of 
coronary heart disease than blood pressure alone in patients >50 years of age (Franklin et 
al., 1999). As well, pulse pressure predicts the risk of stroke and mortality (Domanski et 
al., 1999). There is an increase in pulse pressure in smaller arteries partly due to 
increasing vascular resistance. Peripheral pulse pressure is also increased due to wave 
reflection; the closer you get to a peripheral reflection site, the less the delay between the 
original and reflected waves, and the more their summation affects the pulse amplitude. 
Brachial measurement of pulse pressure reflects arterial stiffness in the peripheral 
vasculature as opposed to the central vasculature (Pauca et al., 1992). If pulse pressure is 
to be used for measurement of arterial stiffness for cardiovascular disease risk 
assessment, it is best to use central aortic blood pressure measurements as opposed to 
peripheral blood pressure, since it has been reported to be a better predictor of 
cardiovascular events (McEniery et al., 2014). In a circulation with compliant arteries, 
pulse pressure tends to be lower than one with increased stiffness, because of the 
Windkessel effect and because the reflected pressure wave tends to return to the aortic 
root during diastole, as opposed to systole. Therefore, the impact of wave reflection on 
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the pulse wave is lower in compliant arteries (Mackenzie et al., 2002). PWV, the rate at 
which the pulse wave travels in a given direction, is one of the most important factors 
contributing to the timing of wave reflection.  
PWV is also a measure of arterial stiffness that can predict cardiovascular risk in a 
state of hypertension (Mackenzie et al., 2002). This measure of stiffness can be calculated 
by dividing the distance (d) between two pressure points by pulse transit time (Dt), the 
time it takes for the pulse to travel this distance;  
PWV = d/Dt 
This technique reflects the stiffness of the aorta, since the pulse travels faster in stiffer 
arteries (Mackenzie et al., 2002). The arterial pressure wave is composed of the forward 
pressure created by systole and the reflected pressure wave. Thus, the foot-to-foot method 
is often used to avoid the influence of wave reflection. With this technique, the time 
between the foot of the central diastolic pressure wave and the foot of the peripheral 
diastolic pressure wave is used to assess pulse transit time (Mackenzie et al., 2002). 
Vascular stiffness, and therefore PWV, has been reported to be dependent on heart rate as 
well as blood pressure. Pulse transit time should therefore be measured at isobaric blood 
pressures and similar heart rates (Butlin et al., 2015; Tan et al., 2012). In clinical practice, 
determination of PWV has been used in the assessment of arterial stiffness, and seems to 
be considered the “gold standard” for evaluating vascular elasticity (Laurent et al., 2006).  
Although PWV is the most common method of assessing arterial stiffness in the 
literature, there are other indices of stiffness that can be measured, such as the elastic 
modulus (Einc), the stiffness index and the augmentation index. Essentially, the elastic 
modulus gives an indication of the elasticity of arteries. It can be defined as the ratio of 
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the force exerted on the blood vessel relative to its deformation, otherwise known as the 
stress to strain ratio. This parameter is defined as incremental, since it is obtained from 
measurements of small changes in blood pressure and vessel diameter (Milnor, 1989). 
The Moens-Korteweg equation can be used to calculate the elastic modulus in vivo, using 
PWV; 
PWV =	 E'()	x	h2rρ  
where Einc = elastic modulus, h = wall thickness, r = lumen radius and ρ = blood density 
(Marque et al., 2001). However, this equation assumes a homogenous vascular wall, as 
well as homogeneous and non-viscous fluid, which is not the case for blood vessels 
studied in vivo (Shahmirzadi et al, 2012). The stiffness index (b) is a measure of the 
mechanical properties of blood vessels, which relates arterial diameter to blood pressure 
(Milnor, 1989). In experimental settings, this index can be obtained by measuring central 
systolic (Ps) and diastolic (Pd) pressures, and systolic (Ds) and diastolic (Dd) lumen 
diameters; 
𝛽 = 	 𝑃1/𝑃3(𝐷1 − 𝐷3)/𝐷3 
The augmentation index is also used as a metric of arterial stiffness. It assesses the 
alteration in the central pressure wave attributed to changes in wave reflection. It is often 
defined as the measurement of the augmentation of central blood pressure by the reflected 
pulse wave (Milnor, 1989). 
Arterial stiffness can be evaluated by assessing a vessel segment (such as a section of 
the aortic wall), or by assessing a larger section of the vasculature (such as the entire 
aorta, assessed by PWV). The limitation of assessing a simple vessel segment, as is the 
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case with the stiffness index, is that it does not accurately reflect the entirety of the 
central vasculature. For example, the increased elasticity in the thoracic aorta compared 
to the abdominal aorta (Wolinsky et al., 1969) could disturb the accuracy of these metrics 
for the assessment of arterial stiffness. Furthermore, many investigations do not seem to 
address the potential effect of blood pressure levels on PWV (McEniery et al., 2003; 
Vuurmans et al., 2003; Wallace et al., 2007; Mahmud and Feely, 2008; Fok et al., 2012). 
This is a major limitation in the current literature, since PWV has been reported to be 
dependent on blood pressure levels; lower blood pressures are associated with lower 
PWV, and higher blood pressures are associated with higher PWV (Tan et al., 2012). 
Correcting for blood pressure (e.g. by measuring PWV at isobaric blood pressures) is of 
great importance to avoid confounding the results, especially when assessing the effect of 
blood pressure lowering drugs on PWV.  
1.3.2 Pathophysiological changes in arterial stiffness 
The mechanical and hemodynamic properties of blood vessels are fundamental 
factors influencing vascular compliance. For example, McEniery and colleagues (2005) 
have observed a positive correlation between increased aortic stiffness and isolated 
systolic hypertension (ISH). Hypertension and acute vascular distention are among the 
main factors that can contribute to an increase in arterial stiffness. Acute distention of 
blood vessels (e.g. by elevated blood pressure) leads to increased stiffness and PWV. Any 
treatment that could ultimately reduce blood pressure, such as the administration of 
sodium nitroprusside (SNP; a NO donor/vasodilator), could alter stiffness and PWV due 
to simple blood pressure alteration. Therefore, measurements of stiffness and PWV must 
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be controlled for blood pressure, especially when comparing stiffness in hypertensive and 
normotensive individuals.  
The architecture of blood vessels makes important contributions to their mechanical 
properties within the circulatory system, to the delivery of blood to organs and tissues in 
the body, and is intimately tied to the elasticity of the vessels involved (Milnor, 1989). 
According to the current literature, the most important pathophysiological alterations that 
occur in arterial stiffness affect the tunica media, the ECM and the endothelium (Zieman 
et al., 2005).  
Similarities between atherosclerosis and arterial stiffness has led to the idea that 
atherosclerosis may contribute to reduced arterial compliance. Atherosclerosis can be 
defined as a cardiovascular disease in which there is accumulation of fatty deposits on 
arterial walls, which can lead to blockage of blood flow. For example, atherosclerosis has 
similar mechanisms to arterial stiffness that alter ECM proteins, such as elastin fracture 
and collagen accumulation. This ultimately leads to an alteration of the mechanical 
properties of arteries (Palombo and Kozakova, 2016).  
The tunica media of blood vessels is composed of VSMCs circumferentially 
arranged around the lumen (Rhodes and Simons, 2007; Todd et al., 1983). Larger arteries 
such as the aorta have a thicker layer of VSMCs than smaller arteries (Marieb and Hoehn, 
2013). Previous work has focused on the involvement of the endothelium and the ECM in 
vascular stiffness (Dao et al., 2005; Wang et al., 2003). The role of VSMCs in arterial 
stiffness is a topic that is increasingly investigated. For example, Sehgel and colleagues 
(2013) confirmed increased stiffness in aortic VSMCs of SH rats compared to WKY rats. 
This was achieved by atomic force microscopy, which consists of applying pressure to a 
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surface (in this case, VSMCs) and measuring the resistance to stress, also known as the 
elastic modulus. Reports from other investigations have indicated increased vascular wall 
thickness in SH rats compared to WKY rats in the thoracic aorta (Marque et al., 1999; 
Van Gorp et al., 1995). In hypertension, increased VSMC mass as well as an increase in 
DNA content in VSMCs (polyploidy) has also been identified in the aorta (Werstiuk and 
Lee, 2000). Brandts and colleagues (2013) investigated the relationship between aortic 
wall thickness (measured with magnetic resonance imaging) and central arterial stiffness 
(assessed by PWV) in hypertensive and normotensive patients. Aortic wall thickness was 
found to be significantly higher in hypertensive compared to normotensive patients, and 
aortic PWV had a strong positive correlation with aortic wall thickness. Thus, the 
increased arterial wall thickness observed in hypertensive subjects has been thought to 
contribute to arterial stiffness in hypertension. The mechanism of involvement of VSMCs 
in the alteration of arterial stiffness is not well understood. However, the involvement of 
the ECM in vascular compliance has been well established (Toda et al., 1980; Basalyga et 
al., 2004; Dao et al., 2005).  
The ECM of the tunica media is largely composed of elastin fibers, which provide 
the elastic properties of the blood vessel (Shekhonin et al., 1987). The ECM of the tunica 
externa, on the other hand, contains mostly collagen (type I and III) (Shekhonin et al., 
1987) as well as nerve fibers (Marieb and Hoehn, 2013). In normal physiological 
conditions, elastin is most involved in the elasticity of the arterial wall (Lehmann, 1999), 
and is also the protein with the highest content in large arteries, such as the aorta (Jacob, 
2003). Collagen fibers, on the other hand, are mostly located in the tunica externa 
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(Marieb and Hoehn, 2013), contribute to the viscoelastic behavior of the vascular wall, 
and maintain the integrity of the arterial wall (Lehmann, 1999). 
In hypertension, arteries are distended due to increased intra-arterial pressures. The 
elastin fibers become acutely distended, and the pressure is transferred to rigid collagen 
fibers. Therefore, arterial stiffness in hypertension is increased partly due to the shift in 
pressure load from the distended elastic fibers to the rigid collagen fibers (Nichols and 
O’Rourke, 2005). Increasing age is another factor that can aggravate arterial stiffness 
(McEniery et al., 2005). With increasing age, the concentration of elastin relative to other 
arterial wall components decreases and is accompanied by an increase in collagen 
content. In addition, age-related arterial wall changes, such as the gradual fragmentation 
of elastin, may also contribute to decreased compliance (Toda et al., 1980). Degradation 
of elastin fibers can occur as a result of matrix metalloproteinase (MMP) activity such as 
MMP-2, which can lead to degradation of ECM proteins. Wang and colleagues (2003) 
have observed age-related increases in MMP-2 activity, and have located MMP-2 in the 
aorta near disintegrated elastin fibers. In addition, the binding of calcium ions to elastin 
fibers calcifies the arterial wall and leads to elastin fragmentation in the media, which 
increases arterial stiffness (Basalyga et al., 2004). Rodrigues and colleagues (2010) have 
also shown that MMPs can cleave β2-AR in SH rats, which could minimize the function 
of β2-AR agonists in SH rats. In addition, this may account for the increased vascular 
tone in SH compared to WKY rats (Fitzpatrick and Szentivanyi, 1980). Calcium levels in 
arterial walls progressively rise with increasing age, accelerating the process of arterial 
stiffening (Reaven and Sacks, 2004). However, the most common hypothesis for the 
degradation of elastin with increasing age is that chronic exposure to systolic pressure 
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within the vascular wall exacerbates the fragmentation of elastin over time (Dao et al., 
2005).  
The role of the endothelium in the alteration of arterial stiffness has been studied 
extensively. The involvement of endothelial cells in altering arterial stiffness has been 
explained by studies investigating the relationships between endothelial dysfunction and 
PWV, as well as the involvement of NO, an endothelium-derived vasodilator, and 
endothelin-1 (ET-1), a potent vasoconstrictor released by the endothelium.  
Endothelial dysfunction and arterial stiffness can appear prior to hypertension. In 
fact, vascular stiffness has been suggested to initiate endothelial cell “contraction”, which 
contributes to increased endothelial stiffness (Huveneers et al., 2015). Wallace and 
colleagues (2007) measured PWV (not corrected for blood pressure) in patients with ISH, 
and determined endothelial function by flow-mediated dilation. They reported higher 
PWV and lower flow-mediated dilation in ISH patients compared to controls. Flow-
mediated dilation is the ability of large arteries to adjust to low blood flow by increasing 
vascular tone, which is largely mediated by NO release (Joannides et al., 1995). 
Endothelium dysfunction occurs when the ability of the endothelium to alter vascular 
tone is impeded. This evidence suggests that there may be a relationship between 
increased aortic stiffness and endothelial dysfunction.  
NO and ET-1 also contribute to the alteration in vascular stiffness in the central 
arteries (Wallace et al., 2007). In addition, Kinlay and colleagues (2001) investigated the 
effect of NO on arterial stiffness. Arterial stiffness was assessed using the Moens-
Korteweg equation for PWV, while Einc was calculated as 75% of the slope of the stress-
strain curves (Einc= 0.75 x stress/strain). The brachial arteries of seven patients were 
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infused with L-NMMA (nitric oxide synthase inhibitor), which initiated an increase in 
PWV. The administration of nitroglycerin (a NO donor), however, was associated with 
reduced PWV. This evidence suggests that NO release has an inverse relationship with 
arterial stiffness in humans. Stiffening of endothelial cells can also result in reduced NO 
production, leading to impairment of VSMC relaxation (Huveneers et al., 2015). The 
association between increased NO levels and the reduction of arterial stiffness has been 
mostly assessed by PWV, since other means of assessing arterial stiffness (such as the 
stiffness index and Moens-Korteweg’s elastic modulus) are dependent on arterial 
diameter.  
An effect of ET-1 on arterial stiffness has been confirmed by Marano and colleagues 
(1999), who reported an increase in arterial compliance in carotid arteries of both SH and 
WKY rats when incubated with ET-1 antagonists in vitro. In addition, Vuurmans and 
colleagues (2003) have observed higher PWV, central systolic blood pressure, as well as 
increased pulse pressure with elevated ET-1 levels in patients with renal failure and/or 
heart failure. Though PWV was not corrected for blood pressure, other investigations 
have found a relationship between ET-1 and arterial stiffness. It has been suggested that 
ET-1 contributes to increased arterial stiffness by inhibiting collagen degradation in 
hypertension (Ergul et al., 2006), which may be attributed to ET-1 mediated smooth 
muscle cell contraction. McEniery and colleagues (2003) investigated the local effects of 
ET-1 on PWV (not corrected for blood pressure) in anesthetized sheep. The infusion of 
ET-1 was accompanied by an increase in PWV, while the infusion of an ET-1 antagonist 
was accompanied by a reduction in PWV. Therefore, ET-1 does seem to have a direct 
effect on arterial stiffness at the local level.  
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1.4 Autonomic nervous system activity and control of arterial blood pressure 
The autonomic nervous system is composed of the sympathetic nervous system 
(SNS) and the parasympathetic nervous system. The SNS innervates vascular smooth 
muscle, and is involved in the regulation of vasomotor tone and blood pressure, and can 
also affect heart rate. The parasympathetic nervous system is involved in the regulation of 
heart rate (Guyenet, 2006). These two systems work together as a component of a 
feedback mechanism termed the baroreflex, which mediates the short-term regulation of 
blood pressure. 
1.4.1 Sympathetic nervous system 
The SNS is often called the fight-or-flight system, and it mediates a number of 
unconscious cardiovascular responses, such as stress-induced increases in heart rate and 
blood pressure. The SNS is composed of preganglionic and postganglionic neurons. 
Preganglionic neurons originate from the thoracic or lumbar regions of the spinal cord 
(Marieb and Hoehn, 2013). The axons of preganglionic neurons in the SNS synapse with 
postganglionic neurons. Postganglionic axons, on the other hand, extend to the organ on 
which it has an effect (Marieb and Hoehn, 2013). They are predominantly adrenergic, 
which means that they mostly secrete noradrenaline (Guyton and Hall, 2011). Negative 
feedback mechanisms mediated by autonomic nerves and hormones can serve to regulate 
arterial pressure through sympathetic nerves (Guyenet, 2006) that innervate VSMCs. 
These sympathetic nerves release norepinephrine, which can stimulate adrenoceptors, 
although it is not the most important regulator of the renin-angiotensin-aldosterone 
system (RAAS) (Marieb and Hoehn, 2013). The SNS influences blood pressure by 
increasing heart rate, vascular tone, as well as the force of cardiac contraction, which 
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leads to an increase in stroke volume and cardiac output (Guyenet, 2006). Furthermore, 
the SNS can initiate venous constriction, which leads to an increase in venous return to 
the heart. Venous constriction can contribute to increasing stroke volume (Charkoudian 
and Rabbitts, 2009). SNS activity can also stimulate the RAAS, which also contributes to 
the regulation of blood pressure and blood volume. The RAAS regulates renin release, 
which subsequently controls angiotensin II and aldosterone levels. Aldosterone causes 
renal tubules to retain sodium and water, while angiotensin II causes vasoconstriction. 
Therefore, the RAAS contributes to maintaining normal blood pressures through the 
release or inhibition of renin (Marieb and Hoehn, 2013). 
1.4.2 Baroreflex  
The baroreceptor reflex also contributes to the rapid control of blood pressure, which 
is mediated by parasympathetic and sympathetic nerves. This reflex relies on 
baroreceptors located in the carotid sinuses and in the aortic arch, which are activated by 
increases in blood pressure. However, if blood pressure decreased suddenly, 
baroreceptors are also capable of decreasing their activity in proportion to the fall in 
blood pressure. With a fall in blood pressure, there is a decrease in the frequency of 
baroreceptor impulses sent to the medulla of the brain, leading to increased activity of the 
vasomotor center. The frequency of action potentials directed to the heart and blood 
vessels by the SNS from the vasomotor center would increase in this case, leading to an 
increase in heart rate and vasoconstriction of the peripheral vasculature, which results in 
an increase in blood pressure. On the other hand, an increase in arterial blood pressure 
stretches the mechanoreceptors in the arterial wall, inhibiting the vasomotor center, which 
leads to a reduction in heart rate and vascular tone. This allows the blood pressure to 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 18	
lower, and ultimately return towards normal (Guyton and Hall, 2011). 
1.4.3 Adrenoceptors  
Adrenoceptors are G protein-coupled receptors (Werstiuk and Lee, 2000) located on 
the cell membranes of sympathetic nerve endings, endothelial cells and/or VSMCs 
(Bulbring and Tomita 1987). They were first discovered in cardiac muscle by Ahlquist, 
(1948) and were subsequently classified in one of two groups, the alpha-adrenoceptors 
(α-AR) or beta-adrenoceptors (β-AR). These adrenoceptors were later discovered to have 
subtypes of their own; among the α-AR subtype, are the α1- and α2-AR. In the 
cardiovascular system, they are mostly located in VSMC membranes and their nerve 
terminals (Bulbring and Tomita 1987). Their activation leads to smooth muscle 
contraction, and inhibition of norepinephrine release from adrenergic terminals (Marieb 
and Hoehn, 2013). There are three β-AR subtypes (β1-, β2-, and β3-AR), which are 
involved in accelerating heart rate (chronotropism; β1-AR), increasing the strength of 
contraction of the heart (inotropism; β1-AR), as well as vasodilation (β2-, and β3-AR) 
(Cohen et al., 1999; Ablad et al., 1974; Dessy et al., 2004). 
1.4.4 Beta-adrenoceptors  
Studies using selective agonists and antagonists allowed the sub-classification of 
beta-adrenoceptors into β1- and β2-AR (Lands et al., 1967). β3-ARs, on the other hand, 
were initially identified in adipocytes, (Emorine et al., 1989) and subsequently in cardiac 
tissue (Cohen et al., 1999). Another β-AR, which was first termed putative β4-AR, was 
discovered in 1989 (Kaumann, 1989). However, this receptor is now termed low-affinity 
β1-AR, and is possibly a distinctive conformational state of the typical β1-AR 
(Granneman, 2001). β1- and β2-AR are usually referred to as the typical β-ARs, and any 
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other receptors, such as β3-AR and the low affinity β1-AR (previously named the putative 
β4-AR) are referred to as atypical β-ARs (Shafiei and Mahmoudian, 1999).  
The release of adrenaline from the adrenal medulla or noradrenaline from autonomic 
nerves can stimulate β-AR activity (Dessy et al., 2004). β1-ARs are usually found in heart 
tissue, where their activation exerts positive inotropic and chronotropic effects (Ablad et 
al., 1974). β2-AR is the predominant adrenoceptor found in VSMCs (Brodde and Michel, 
1992; Takata and Kato, 1996). However, β1-AR and an atypical β-AR resembling the low 
affinity β1-AR have also been identified in VSMCs (Brawley et al., 2000). β2-AR has 
been identified throughout the cardiovascular system, such as in the rat thoracic aorta 
(Brawley et al., 2000), carotid arteries (Chiba and Tsukuda, 2001), and heart tissue 
(Morisco et al., 2001). In the vasculature, β2-ARs are predominantly involved in 
adrenergic-mediated peripheral vasodilation, although the activation of β1-AR also 
reduces vascular tone. Relaxation induced by isoprenaline (non-selective β1- and β2-AR 
agonist) was not attenuated by NO release inhibition or ‘disruption’ of the endothelium, 
indicating that the relaxation was not endothelial-dependent, and presumably had a direct 
effect upon VSMCs (Chruscinski et al., 2001). β3-ARs are located in the cell membranes 
of cardiomyocytes (Cohen et al., 1999), adipose tissue (Ferrer-Lorente, 2005), and the 
endothelium (Trochu et al., 1999). β3-ARs are involved in contractile effects in the heart 
(Cohen et al., 1999), and have been shown to mediate direct VSMC relaxation in the rat 
abdominal aorta (Matsushita et al., 2006). β3-AR stimulation with a selective agonist, 
BRL37344, also caused relaxation in denuded internal mammary arteries (Shafiei and 
Mahmoudian, 1999). The rat thoracic aorta also seems to relax in response to activation 
of atypical receptors, such as β4-AR (low affinity β1-AR) (Brawley et al., 2000). β-ARs 
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can be found throughout the vascular system, and are intimately involved in the control of 
vascular tone and heart rate.  
Structure	and	Pathway	
β-ARs are G-coupled receptors composed of seven transmembrane helices of amino 
acids. Their glycosylation sites are at the amino terminus (Lefkowitz, 2007), where 
norepinephrine or epinephrine may bind (Marieb and Hoehn, 2013). β-agonists activate a 
stimulatory G protein (Gs), which stimulates adenylyl cyclase. Adenylyl cyclase converts 
ATP to cyclic adenosine monophosphate (cAMP). This increase in cAMP results in the 
activation of protein kinase A (PKA), which leads to phosphorylation of proteins. This 
results in a decrease in intracellular Ca2+ levels, leading to relaxation (Figure 2). 
(Werstiuk and Lee, 2000)  
These receptors can be stimulated by selective or non-selective β-agonists. For 
example, selective beta-agonists such as terbutaline, a selective β2-agonist, (Johansson, 
1995) and BRL37344, a selective β3-agonist (Candelore et al., 1999), target specific beta-
adrenoceptors. Others, such as isoprenaline, a non-selective β1- and β2-agonist, (Gao et 
al., 2010) are recognized as non-selective since they target more than one subtype of β-
AR.  
1.4.5 Beta-adrenoceptors and hypertension  
In essential hypertension, SNS activity is increased, and baroreflex mechanisms 
seem to be attenuated (Lucini et al., 1994). In addition, impaired β-AR mediated 
relaxation has also been identified in the thoracic aorta of SH rats (Cheng and Shibata, 
1981). Ageing has also been linked to a decrease in β-AR–Gs–adenylyl cyclase coupling, 
downregulation of β-AR, modifications in G-protein levels (Werstiuk and Lee, 2000), 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 21	
and lower β-AR activity (Fleisch et al., 1970). In addition, Bray and colleagues (2000) 
reported a significant relationship between blood pressure and polymorphisms in the β2-
AR gene. For example, they reported increased frequency of Gly16 and Glu27 alleles in 
the β2-AR gene of hypertensive compared to normotensive subjects. This evidence 
supports the idea that β2-AR may have an important role in hypertension. Mallem and 
colleagues (2004) have identified an up-regulation of β3-ARs in the endothelial layer of 
the aorta of SH rats by immunohistochemistry, which did not accompany an increase in 
β3-AR vasodilatory response. The current literature suggests that β-AR expression and 
activity is modified in pathophysiological conditions such as hypertension. It has been 
suggested that β-AR blockade is associated with an impairment of relaxations of the 
conduit blood vessels and this could significantly contribute to increased vascular 
stiffness (Klapholz, 2009; Dudenbostel and Glasser, 2012). However, the role of β-AR in 
the alteration of arterial stiffness is still not established. 
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Figure 2. Typical beta-adrenoceptor pathway. Norepinephrine or epinephrine binds to the 
β-adrenoceptor, activate Gs, which activates adenylyl cyclase. Adenylyl cyclase then 
converts ATP to cAMP, which will activate a protein kinase (PKA), which leads to the 
phosphorylation of proteins. Adapted from (Santulli and Iaccarino, 2013), used under 
Creative Commons Attribution License. 
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1.4.6 Beta-adrenoceptor blockade and hypertension 
β-blockers are a class of drugs used for lowering high blood pressure. These 
competitive antagonists essentially prevent norepinephrine and noradrenaline from 
stimulating β-ARs (Haeusler, 1990; Girard et al., 1995). They may contribute to lowering 
blood pressure by decreasing heart rate, which can lead to a decrease in cardiac output. In 
addition, treatment with β-blockers inhibits β1-AR-mediated renin secretion, which 
decreases angiotensin II and aldosterone levels (Laragh, 2001). With decreased levels of 
aldosterone, renal tubules cannot retain as much sodium and water, which could 
ultimately lead to lowering of blood volume and blood pressures.  
The first generation of β-blockers includes non-selective drugs such as propranolol. 
The second generation of β-blockers is β1-selective, also known as cardioselective, since 
their primary action is reduction in heart rate. Finally, the third generation of β-blockers 
is those who have additional vasodilatory effects in addition to simple beta-blockade, 
such as nebivolol (Pederson and Cockroft, 2006). Although non-selective β-blocker 
hypertension treatments also block β2-AR, the vasoconstriction is minimal due to these 
additional therapeutic effects. Propranolol was among the first β-blockers, and was used 
for the treatment of angina (Quirke, 2006). Angina is a cardiovascular disorder associated 
with chest pain, often caused by insufficient blood flow to the heart due to coronary 
artery spasms or blockage. Scientists later modified the structure of various beta-blockers 
to add further cardiovascular benefits including β1-AR selectivity, intrinsic 
sympathomimetic activity (partial agonists), α-AR blockade, and vasodilation (NO 
donors) (Frishman, 1981).  
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Some β-blockers selectively target β1-ARs, such as metoprolol and atenolol 
(Frishman, 1984). According to Del Colle and colleagues (2007), both β1- selective and 
non-selective β-blockers have a similar effect in a state of hypertension. β-blockers 
usually lower blood pressure by lowering heart rate by blocking the activity of β1-ARs, 
however other β-blockers have also been developed with secondary mechanisms to 
reduce blood pressure (Frishman, 1984). For example, some β-blockers have intrinsic 
sympathomimetic activity; they can act as β-blockers, and act as competitive antagonists 
of norepinephrine and epinephrine to oppose the effects of catecholamines (Jaillon et al., 
1990). For example, partial agonists like pindolol also stimulate β-receptors, but are only 
partially effective in comparison to typical agonists (Frishman, 1984). These β-blockers 
cause vasodilation and a reduction in heart rate, which decreases peripheral vascular 
resistance and blood pressure (in small doses). Other β-blockers also block α-AR and/or 
β-AR, such as labetalol and carvediol (Frishman, 1984). These α-blocking properties 
cause vasodilation, which reduces peripheral vascular resistance. Other β-blockers are 
NO donors, such as nebivolol, and stimulate NO production through activation of 
endothelial nitric oxide synthase (eNOS), thus increasing vasodilation (Maffei et al., 
2006).  
1.5 Rationale  
Currently, there is very little known of the nature and role of the adrenergic-mediated 
responses as a contributor to arterial stiffness. The effects of β-AR stimulation on arterial 
stiffness have received little attention. Therefore, this project was aimed at systemically 
determining how activating β-AR affects vascular stiffness in a state of high compared to 
normal intravascular arterial pressure.  
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The SNS plays a pivotal role in the control of vascular function through the 
activation of adrenoceptors (Guyenet, 2006). Accordingly, beta-adrenergic blockers are 
commonly and widely used in the treatment of a host of cardiovascular disorders. It has 
been suggested that these drugs do not lower central aortic systolic and pulse pressure but 
seem to only lower arterial blood pressure at the distal circulation (Klapholz, 2009; 
Williams et al., 2006). Thus, it has been implied that the lack of vascular relaxation may 
be responsible for increased arterial stiffness (Dudenbostel and Glasser, 2012). 
Essentially, the use of β-blockers has been suggested to be associated with an impediment 
in relaxation of the conduit blood vessels and may significantly contribute to increased 
vascular stiffness, consequently increasing the risk of morbidity and mortality. 
Nevertheless, little is known of the effects of β-AR on vascular stiffness, which will be 
the main topic addressed in this thesis.  
In clinical practice, determination of PWV has been used in the assessment of arterial 
stiffness, and is considered the “gold standard” for evaluating vascular elasticity (Laurent 
et al., 2006). The measure of aortic stiffness is pressure-dependent due to the structural 
properties of the arterial wall (Shadwick, 1999). Therefore, we chose to use PWV as our 
measure of vascular stiffness, and made our measurements of PWV over a similar range 
of pressures (85-95 mmHg with venous occlusion) for consistency throughout all groups. 
We used the foot-to-foot approach to measure pulse transit time, since this approach has 
been suggested to be valid for assessing pulse transit time in rodents (Mitchell et al., 
1997). To obtain adequate transit time for our measurements, we measured the pulse 
transit time from the aortic arch to the bifurcation of the femoral arteries. Due to the 
greater elasticity of the thoracic aorta in comparison to the abdominal aorta, PWV 
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measured in this investigation is mostly from the thoracic aorta, which produces a slower 
PWV than that of the abdominal aorta. 
In the current investigation, the SH rat was used as a model of hypertension due to 
the similar pathophysiology in humans (Pinterova et al., 2011), and WKY were used as 
normotensive controls for comparison with SH rats. β-AR agonists were infused in SH 
and WKY rats to determine the effect of β-AR stimulation on PWV (isoprenaline, β1- and 
β2-AR; terbutaline, β2-AR; BRL37344, β3-AR). Isoprenaline is amongst the most potent 
β-AR agonists (Apperley et al., 1976). Terbutaline and BRL37344 were used in this study 
due to their selectivity for β2- and β3-AR, respectively (O’Donnell and Wanstall, 1976; 
Vulliemoz et al., 1975; Lofdahl et al., 1983; Trochu et al., 1999; Brawley, 2000).  
Beta-blockers such as NO donors or those with sympathomimetic activity have a 
multitude of effects in addition to beta-blockade. We therefore decided to use beta-
agonists to better understand how beta-adrenoceptor activity influences arterial stiffness, 
without needing to address the confounding effects that come with the use of beta-
blockers. Further studies using beta-blockers will be useful in assessing the therapeutic 
value of beta-blocker therapy in high systemic arterial pressure due to increased vascular 
stiffness. In addition, sodium nitroprusside (vasodilator) was infused in SH and WKY 
rats to determine the effect of potent and non-selective relaxation of VSMC on PWV. 
Furthermore, there is currently a lack of literature on β-AR expression and activity in the 
abdominal aorta. Thus, we decided to determine the expression of the different subtypes 
of β-AR using immunofluorescence analysis.  
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1.6 Objectives 
The objectives of this investigation were to define the role of different subtypes of 
beta-adrenoceptors in the control of arterial stiffness, as assessed by PWV. The present 
investigation will: 
1. Investigate the effects of sub-types of β-AR (β1, β2 and/or β3) on PWV, using β-
AR agonists (isoprenaline, terbutaline, BRL37344). 
2. Determine whether a state of high intravascular pressure alters the contributions 
of β-AR in reducing PWV in SH rats. 
3. Determine the expression of β-AR in the abdominal aorta. 
4. Determine whether vasodilation (with SNP), independent from β-AR stimulation, 
reduces PWV in a state of hypertension and normotension.  
1.7 Hypothesis 
Two main hypotheses were addressed in the current investigation. First, the 
activation of β-AR leads to a reduction in PWV, an index of arterial stiffness. Secondly, 
the reduction in arterial stiffness is due to relaxation of the large central arteries such as 
the aorta, as opposed to a reduction in blood pressure alone.   
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2. Materials and Methods  
All procedures on animals were carried out in accordance with the guidelines of the 
Canadian Council on Animal Care, with the approval of the Institutional Animal Care 
Committee of Memorial University of Newfoundland. All animals were kept in a 
temperature-controlled environment (22 ± 2°C) on a 12h-12h light-dark cycle, and had 
access to normal tap water and standard chow ad libitum. Animals were purchased from 
Charles River Laboratories International, Inc. (USA). 
2.1 Surgical preparation of animals 
WKY and SH rats were anesthetized (induction 5% isoflurane in 100% oxygen, 
maintenance 1.5-1.75% in 100% oxygen), and were injected with buprenorphine (0.01 
mg/kg s.c.). Core body temperature was maintained at 37 ± 1°C using a heating lamp and 
monitored with a rectal thermometer. The left femoral and carotid arteries were isolated 
and catheterized (polyethylene tubing; I.D. 0.58 mm, O.D. 0.965 mm connected to I.D. 
0.28 mm, O.D. 0.61 mm). The catheters were advanced approximately 2 cm. The left 
femoral vein was also isolated and catheterized (polyethylene tubing; I.D. 0.58 mm, O.D. 
0.965 mm). All catheters were filled with heparinized normal saline (25 iu/ml). Animals 
were stabilized for 45-60 min, and continuous central (aortic arch) and peripheral (left 
femoral artery) blood pressure, as well as heart rate was recorded by AcqKnowledge 
(3.9.1.6) software (Biopac Systems Canada Inc.) with a pressure transducer (P23XL; 
Spectramed Statham). The signals were then amplified (DA 100A; Biopac Systems Inc.), 
where the amplifier was connected to a universal interface module (UIM 100; Biopac 
Systems Inc.), and to an acquisition unit (MP100; Biopac Systems Inc.). The analog 
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output signal was then converted to a digital signal (USB1W; Biopac Systems Inc.), and 
displayed in AcqKnowledge (3.9.1.6). 
2.2 Experimental protocol 
Male WKY and SH rats of 13-14 weeks of age were assigned to one of the following 
five treatment subgroups: normal saline (time control), sodium nitroprusside 
(vasodilator), isoprenaline (β1- and β2-AR agonist), terbutaline (β2-AR agonist), and 
BRL37344 (β3-AR agonist). 
After the stabilization period, baseline blood pressure and heart rate were recorded 
for 20 min before three cumulative doses (isoprenaline: 0.001, 0.003, & 0.01 µg/kg/min; 
terbutaline, 1, 3, & 10 µg/kg/min; BRL37344, 1, 3, & 10 µg/kg/min; and sodium 
nitroprusside, 1, 3, & 10 µg/kg/min) were continuously infused for 20 min. A pilot study 
was conducted to identify drug doses that would ensure adequate reduction in blood 
pressure with terbutaline, BRL37344 and SNP. The pilot study was also used to 
determine doses of isoprenaline that could modestly decrease blood pressure, while 
avoiding an increase in heart rate (which could affect PWV independently from β-AR 
stimulation). Equivalent volumes of normal saline were infused for parallel time-control 
groups (infusion rates: 0.002, 0.006, & 0.02 ml/min). Central aortic and peripheral blood 
pressures as well as heart rate were continuously monitored throughout the experiments.  
Following the completion of each experiment, animals were sacrificed by anesthetic 
overdose, KCl injection and thoracotomy. A piece of silk suture was then placed between 
the tips of the carotid and femoral catheters (post-mortem), to measure the distance (d) (in 
mm) between the two points where blood pressure was captured. A section of the 
abdominal aorta below the kidney and above the bifurcation of femoral arteries of four 
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saline-treated animals (WKY, n=4; SH, n=4) was excised and placed in 10% neutral 
buffered formalin (pH=7.4). Each blood vessel segment was embedded in paraffin for 
immunofluorescence investigations. The heart of each animal was also excised, and the 
right ventricle and left ventricle plus septum were separated and weighed. 
2.3 Immunofluorescence  
Immunofluorescence was used to identify β1-, β2-, and β3-adrenoceptors in the rat 
abdominal aorta. Sections from saline groups (WKY: n = 4, SH: n = 4) were stained and 
imaged for immunofluorescence analysis. Immunofluorescence protocols were similar to 
those of Daneshtalab and colleagues (2010). Dilutions of antibodies were adjusted to 
ensure selective staining of tissues. 
Paraffin embedded tissues were cut in 6 µm sections, deparaffinized in xylene, and 
rehydrated with decreasing concentrations of ethanol. 3% Hydrogen peroxide was then 
added to the tissues for 15 min to block endogenous peroxidase. Heated citrate buffer (pH 
6.0) [1.92 g/l] (10 min) was used as antigen retrieval for β1-AR sections, and 1% sodium 
dodecyl sulfate (SDS) (3 min) was used as antigen retrieval for β2- and β3-AR sections. 
All samples were placed in a humidifier with 10% normal goat serum (NGS) with 0.1% 
triton x in phosphate-buffered saline (PBS) to block for 1h-2h. Sections were then 
incubated overnight at 4 °C with primary rabbit polyclonal β1-, β2-, or β3-AR antibodies 
(β1-AR; 1:200, β2-AR: 1:150, β3-AR: 1:50) in 2% NGS in PBS. Each section was washed 
in phosphate-buffered saline (PBS) after every step for 3-5 min on a shaker. 
The following day, tissues were washed with tris-buffered saline (TBS) four times 
for 10 min on a shaker. Secondary antibodies were prepared in the dark, then applied to 
the sections in a humidifier and left for 30 min. Secondary antibodies consisted of Cy5 
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goat anti-rabbit IgG (β1- and β2-AR; 1:500, β3-AR; 1:600) and 4’ 6-diamidino-2-
phenylindole (DAPI; 1:1000) in 2% NGS in TBS. Slides were once again washed with 
TBS four times for 10 min on a shaker, and covered with 50% glycerol in PBS to be 
cover-slipped and sealed with clear nail polish.  
Sections from the abdominal aorta of SH and WKY rats (n=4) were imaged with 
confocal microscopy at 20x optical magnification and 1.9x digital magnification, and 
analyzed with Fluoview software (Olympus Fluoview, FV100). Laser parameters 
(intensity, offset and transmitted light) were the same within each staining group (β1-, β2- 
and β3-AR). 
Images were then analyzed with ImageJ software (National Institutes of Health, 
ImageJ1.40). First, the images were calibrated and gray scaled. Afterwards, background 
integrated density and mean integrated density were measured. The corrected mean 
density value (CMDV) was used, where CMDV=MDV – MBDV; MDV is mean density 
value, and MBDV is mean background density value. The mean of three background 
value measurements was used for MBDV. The mean of CMDV in WKY (n=4) and in SH 
(n=4) was used for comparison of β-AR density between groups. 
2.4 Data measurements and calculations: 
Arterial stiffness was determined by measuring PWV (Figure 3). Since PWV is 
pressure-dependent and needs to be measured in a pressure-normalized state, the 
following method was used to calculate PWV: prior to drug infusions, pressure was 
applied to the inferior vena cava (by abdominal compression) to temporarily reduce 
venous return, with the objective of capturing a diastolic pressure of 85-95 mmHg for 
PWV measurements in all animals.   
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 Figure 3. Pulse wave velocity (PWV) was calculated by dividing the distance between 
two pressure points (A) by the pulse transit time (B). Pulse transit time is the time it takes 
for the pulse to travel along the vasculature.  
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Pressure was then released, and blood pressure was allowed to stabilize (Butlin et al., 
2015). PWV was measured at baseline (post blood-flow occlusion) and 10-20 min after 
the start of each dose. PWV was calculated by dividing the distance (d) between the tip of 
the carotid artery catheter and the tip of the femoral artery catheter (measured prior to the 
excision of the abdominal aorta) by pulse transit time (Dt), the time it takes for the pulse 
to travel this distance;  
PWV = d/Dt 
2.5 Statistical analyses  
Baseline values were compared with two-way analysis of variance (ANOVA) to 
determine if there were differences between group means. Drug treatment values were 
compared to saline time-control values with one-way ANOVA (Tukey test as needed) to 
determine significance between means. Hemodynamic values in all drug infusion groups 
were compared to their respective saline-infused time-control. ANOVA was used to 
compare the CMGV of the different subtypes of β-AR. A p<0.05 was the criterion for 
statistical significance for all comparisons. All statistical analyses were done using Sigma 
Plot 12.2.0.45. In total, 132 experiments have been conducted, 69 of which were included 
in the final analysis. After extraction of the heart, 11 WKY rats were excluded from the 
final analysis due to heart defects such as three ventricles. 3 SH and 23 WKY rats were 
also excluded due to abnormal resting heart rate and/or blood pressure at baseline. The 
remaining 26 experiments were excluded due to missing data, experimental or 
measurement errors.  
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2.6 Chemicals 
All drugs were dissolved in 0.9% saline. Isoflurane was purchased from CDMV 
(Halifax, Canada), buprenorphine from Schering Plough Ltd (UK), heparin from SoloPak 
Laboratories Inc. (USA), isoprenaline from Winthrop Laboratories (USA), terbutaline 
and SNP from Sigma Aldrich (USA), and BRL37344 from Tocris Bioscience (UK). β1-
AR antibodies were purchased from Abcam Inc. (Toronto, ON), β2- and β3-AR antibodies 
from Santa Cruz (USA), Cy5 goat anti-rabbit IgG	and normal goat serum from Jackson 
ImmunoResearch Laboratories Inc. (USA), DAPI, 10x PBS, tris base and triton X-100 
from Fisher Scientific Inc. (USA), and citric acid from Sigma Aldrich (USA). 
  
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 35	
3. Results 
There were no significant differences in body weight between SH and WKY rats 
(282 ± 4g vs. 290 ± 4g). The ratio of the left ventricle plus septum to right ventricle of SH 
rats (4.0 ± 0.1) was statistically greater than that in WKY (3.3 ± 0.1), which is an 
indication of left ventricular hypertrophy likely due to systemic hypertension.  
3.1 Baseline hemodynamics 
The baseline hemodynamic values are shown in Table 2. SH animals had 
significantly higher systolic and diastolic (central and peripheral) blood pressures than 
WKY rats. Also, the mean central and peripheral blood pressures of SH rats (132 ± 2 
mmHg & 125 ± 2 mmHg) were significantly higher than those of WKY (90 ± 2 mmHg & 
83 ± 2 mmHg) rats, respectively. Pulse pressures (central & peripheral) were significantly 
greater in SH compared to WKY rats. In addition, central pulse pressure was significantly 
different from peripheral pulse pressure in both WKY and SH animals. To compare PWV 
at isobaric blood pressures, 71% of measurements were captured at a diastolic pressure of 
85-95 mmHg (the remaining measurements were captured within 15% of this range). 
PWV was significantly higher in SH rats compared to WKY at baseline. There was no 
significant difference in heart rate between WKY and SH rats (Table 2). 
3.2 Sodium nitroprusside 
Sodium nitroprusside (vasodilator; 1, 3 & 10 µg/kg/min) was infused in SH and 
WKY rats to determine the effect of potent and non-selective relaxation of VSMCs on  
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Table 2. Baseline values for central systolic blood pressure (cSBP; mmHg), central 
diastolic blood pressure (cDBP; mmHg), peripheral systolic blood pressure (pSBP; 
mmHg), peripheral diastolic blood pressure (pDBP), central pulse pressure (cPP; mmHg), 
peripheral pulse pressure (pPP; mmHg), heart rate (HR; beats/minute) and pulse wave 
velocity (PWV; m/s; measured at central diastolic pressures between 85-95 mmHg post-
blood flow occlusion) of Wistar-Kyoto (WKY) and spontaneously hypertensive (SH) rats 
in saline, isoprenaline, terbutaline, BRL37344, and sodium nitroprusside (SNP) groups. 
Each value is mean ± SEM. n = 6-8. 
  Saline Isoprenaline Terbutaline BRL37344 SNP 
 cSBP 103 ± 4 103 ± 3 110 ± 5 113 ± 3 100 ± 4 
WKY 
cDBP 79 ± 4 82 ± 3 84 ± 4 89 ± 3 75 ± 3 
pSBP 107 ± 6 110 ± 4 119 ± 5 119 ± 6 104 ± 7 
pDBP 64 ± 4 67 ± 3 74 ± 4 76 ± 4 64 ± 3 
cPP 24 ± 2 22 ± 1 25 ± 3 25 ± 3 25 ± 3 
pPP 44 ± 3a 43 ± 2a 45 ± 2a 43 ± 3a 40 ± 4a 
HR 317 ± 9 324 ± 8 335 ± 12 338 ± 7 313 ± 10 
PWV 6.5 ± 0.4 7.1 ± 0.3 7.4 ± 0.2 6.3 ± 0.6 6.0 ± 0.7 
 cSBP 149 ± 5b 165 ± 7b 153 ± 6b 155 ± 3b 147 ± 5b 
SH 
cDBP 117 ± 5b 128 ± 6b 119 ± 5b 122 ± 3b 115 ± 3b 
pSBP 158 ± 5b 177 ± 8b 162 ± 7b 161 ± 3b 154 ± 5b 
pDBP 100 ± 4b 115 ± 7b 106 ± 5b 109 ± 4b 100 ± 3b 
cPP 32 ± 2b 37 ± 2b 34 ± 3b 33 ± 2b 32 ± 3b 
pPP 58 ± 2ab 62 ± 2ab 56 ± 4ab 52 ± 4ab 54 ± 3ab 
HR 338 ± 9 329 ± 11 339 ± 9 338 ± 7 342 ± 15 
PWV 10.3 ± 1.1b 8.7 ± 0.7b 9.6 ± 0.9b 9.1 ± 0.9b 8.3 ± 0.7b 
 
aSignificantly different from cPP within strain; p < 0.05 
bSignificantly different from respective value in WKY; p < 0.05 
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PWV. The infusion of SNP significantly decreased PWV at all doses in SH rats, but not 
at any dose in WKY when compared to saline-infused time-controls (Figure 4). SNP 
infusions significantly decreased both central and peripheral pulse pressures at the two 
highest doses in SH rats, but not at any dose in WKY (Figure 5 and Figure 6). 
Administration of SNP also significantly decreased central systolic and diastolic blood 
pressures in SH rats at the highest two doses, but not at any dose in WKY rats (Figure 7 
and Figure 8). SNP infusions did not alter heart rate in WKY or SH rats (Figure 9). 
3.3 Terbutaline 
       Terbutaline (selective β2-AR agonist; 1, 3, & 10 µg/kg/min) was infused in SH and 
WKY rats to determine the effect of β2-AR stimulation on PWV. The infusion of 
terbutaline significantly decreased PWV at the two lowest doses in SH rats, but not at any 
dose in WKY rats (Figure 4). Administration of terbutaline at all doses significantly 
decreased central systolic and diastolic blood pressures in SH rats, and at the highest dose 
in WKY rats (Figure 7 and Figure 8). The infusion of terbutaline significantly increased 
heart rate in SH rats at the highest dose, but not at any dose in WKY rats (Figure 9). 
Terbutaline infusions did not alter central or peripheral pulse pressure in WKY or SH rats 
(Figure 5 and Figure 6). 
3.4 BRL37344 
       BRL37344 (selective β3-AR agonist; 1, 3, & 10 µg/kg/min) was infused in SH and 
WKY rats to determine the effect of β3-AR stimulation on PWV. The infusion of 
BRL37344 significantly increased heart rate in hypertensive animals at the highest dose, 
but not in WKY rats (Figure 9). BRL37344 significantly decreased central systolic and 
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Figure 4. Pulse wave velocity (PWV) during infusions of equivalent volumes of saline 
(n=6; 0.002, 0.006, 0.02 ml/min) and increasing doses of isoprenaline (n=7; 0.001, 0.003, 
0.01 µg/kg/min), terbutaline (n=7), BRL37344 (WKY n=6; SHR n=8) and sodium 
nitroprusside (SNP; WKY n=7; SHR n=8) (1, 3, 10 µg/kg/min) for 20 minutes each in 
(A) Wistar-Kyoto and (B) spontaneously hypertensive rats at 13-14 weeks of age. B, 
baseline; D1, dose 1; D2, dose 2; D3, dose 3. Values are mean ± SEM. 
aSignificantly different from respective value in saline-infused time-control group; 
p<0.05 
bSignificantly different from respective value in WKY rats; p<0.05   
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Figure 5. Central pulse pressure during infusions of equivalent volumes of saline (n=6; 
0.002, 0.006, 0.02 ml/min) and increasing doses of isoprenaline (n=7; 0.001, 0.003, 0.01 
µg/kg/min), terbutaline (n=7), BRL37344 (WKY n=6; SHR n=8) and sodium 
nitroprusside (SNP; WKY n=7; SHR n=8) (1, 3, 10 µg/kg/min) for 20 minutes each in 
(A) Wistar-Kyoto and (B) spontaneously hypertensive rats at 13-14 weeks of age. B, 
baseline; D1, dose 1; D2, dose 2; D3, dose 3. Values are mean ± SEM. 
aSignificantly different from respective value in saline-infused time-control group; 
p<0.05 
bSignificantly different from respective value in WKY rats; p<0.05	 	
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Figure 6. Peripheral pulse pressure during infusions of equivalent volumes of saline 
(n=6; 0.002, 0.006, 0.02 ml/min) and increasing doses of isoprenaline (n=7; 0.001, 0.003, 
0.01 µg/kg/min), terbutaline (n=7), BRL37344 (WKY n=6; SHR n=8) and sodium 
nitroprusside (SNP; WKY n=7; SHR n=8) (1, 3, 10 µg/kg/min) for 20 minutes each in 
(A) Wistar-Kyoto and (B) spontaneously hypertensive rats at 13-14 weeks of age. B, 
baseline; D1, dose 1; D2, dose 2; D3, dose 3. Values are mean ± SEM. 
aSignificantly different from respective value in saline-infused time-control group; 
p<0.05 
bSignificantly different from respective value in WKY rats; p<0.05  
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Figure 7. Central systolic blood pressure during infusions of equivalent volumes of saline 
(n=6; 0.002, 0.006, 0.02 ml/min) and increasing doses of isoprenaline (n=7; 0.001, 0.003, 
0.01 µg/kg/min), terbutaline (n=7), BRL37344 (WKY n=6; SHR n=8) and sodium 
nitroprusside (SNP; WKY n=7; SHR n=8) (1, 3, 10 µg/kg/min) for 20 minutes each in 
(A) Wistar-Kyoto and (B) spontaneously hypertensive rats at 13-14 weeks of age. B, 
baseline; D1, dose 1; D2, dose 2; D3, dose 3. Values are mean ± SEM.	
aSignificantly different from respective value in saline-infused time-control group; 
p<0.05 
bSignificantly different from respective value in WKY rats; p<0.05 	
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Figure 8. Central diastolic blood pressure during infusions of equivalent volumes of 
saline (n=6; 0.002, 0.006, 0.02 ml/min) and increasing doses of isoprenaline (n=7; 0.001, 
0.003, 0.01 µg/kg/min), terbutaline (n=7), BRL37344 (WKY n=6; SHR n=8) and sodium 
nitroprusside (SNP; WKY n=7; SHR n=8) (1, 3, 10 µg/kg/min) for 20 minutes each in 
(A) Wistar-Kyoto and (B) spontaneously hypertensive rats at 13-14 weeks of age. B, 
baseline; D1, dose 1; D2, dose 2; D3, dose 3. Values are mean ± SEM. 
aSignificantly different from respective value in saline-infused time-control group; 
p<0.05 
bSignificantly different from respective value in WKY rats; p<0.05	 	
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Figure 9. Heart rate during infusions of equivalent volumes of saline (n=6; 0.002, 0.006, 
0.02 ml/min) and increasing doses of isoprenaline (n=7; 0.001, 0.003, 0.01 µg/kg/min), 
terbutaline (n=7), BRL37344 (WKY n=6; SHR n=8) and sodium nitroprusside (SNP; 
WKY n=7; SHR n=8) (1, 3, 10 µg/kg/min) for 20 minutes each in (A) Wistar-Kyoto and 
(B) spontaneously hypertensive rats at 13-14 weeks of age. B, baseline; D1, dose 1; D2, 
dose 2; D3, dose 3. Values are mean ± SEM.	
aSignificantly different from respective value in saline-infused time-control group; 
p<0.05 
bSignificantly different from respective value in WKY rats; p<0.05 
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diastolic blood pressures at all doses in SH rats. However, it had no effect on central 
systolic and diastolic blood pressures of WKY rats (Figure 7 and Figure 8). The infusion 
of BRL37344 had no effects on PWV (Figure 4), as well as central and peripheral blood 
pressures in WKY and SH rats. 
3.5 Isoprenaline 
       Isoprenaline (non-selective β1- and β2-AR agonist; 0.001, 0.003, & 0.01 µg/kg/min) 
was infused in SH and WKY rats to determine the effect of simultaneous β1- and β2-AR 
stimulation on PWV. The infusion of isoprenaline significantly decreased central 
diastolic blood pressure in SH rats at the highest dose, but not at any dose in WKY rats 
(Figure 8). The infusion of isoprenaline had no effect on PWV (Figure 4), as well as 
central and peripheral pulse pressure in WKY or SH rats (Figure 5 and Figure 6). 
Administration of isoprenaline did not significantly decrease central systolic pressure in 
WKY or SH rats (Figure 7). In addition, the administration of isoprenaline and SNP did 
not significantly affect heart rate in WKY or SH rats (Figure 9). 
3.6 Presence of beta-adrenoceptors on the abdominal aorta 
       Corrected mean density values are shown in Table 3. Immunofluorescence revealed 
the expression of β1-, β2- and β3-AR on endothelial cells, VSMCs and in the adventitial 
tissue of both WKY and SH rats (Figure 10, Figure 11, and Figure 12). Quantification of 
the density of β-AR indicated significantly higher expression of β1-AR in the 
endothelium in comparison to VSMCs in both WKY and SH rats. However, there were 
no significant differences in the expression of β2- and β3-AR between the endothelium 
and the vascular smooth muscle. In addition, no significant differences in expression of 
β1-, β2-, or β3-AR were found between WKY and SH rats.  
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Table 3. Corrected mean density values (arbitrary units) of β1-, β2- and β3-adrenoceptors 
in vascular smooth muscle cells (VSMC) and the endothelium of the abdominal aorta of 
13-14 week old Wistar-Kyoto (WKY; n=4) and spontaneously hypertensive (SH; n=4) 
rats. Each value is mean ± SEM. 
  WKY SH 
VSMC 
β1-AR 11 ± 1 9 ± 2 
β2-AR 21 ± 4 15 ± 2 
β3-AR 21 ± 4 15 ± 2 
Endothelium 
β1-AR 23 ± 3a 26 ± 4a 
β2-AR 24 ± 4 16 ± 2 
β3-AR 26 ± 4 18 ± 3 
aSignificantly different from respective value in VSMC within strain; p < 0.05 
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Figure 10. Typical immunofluorescence expression of β1-adrenoceptor expression in 
abdominal aortas of WKY (A) and SH (B) rats. 	
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 47	
A  
 
 
 
B  
 
 
 
Figure 11. Typical immunofluorescence expression of β2-adrenoceptor expression in 
abdominal aortas of WKY (A) and SH (B) rats.  
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Figure 12. Typical immunofluorescence expression of β3-adrenoceptor expression in 
abdominal aortas of WKY (A) and SH (B) rats.  
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4. Discussion 
The aim of this investigation was to define the role of different subtypes of beta-
adrenoceptors in the control of arterial stiffness in the rat aorta, as assessed by PWV. The 
main findings of this investigation indicate that the stimulation of β2-AR (but not β1- or 
β3-AR) reduced PWV in SH rats, but not in WKY rats. The administration of SNP also 
reduces PWV in SH rats, but not in WKY rats. Since PWV was measured within a small 
range of blood pressures in all of our subjects, the alterations in PWV observed are 
independent from its effects on blood pressure. Furthermore, immunofluorescence results 
suggested that all three subtypes of β-AR were expressed on endothelial cells, VSMC and 
in the adventitial tissue of the abdominal aorta in both WKY and SH rats. The data also 
revealed greater expression of β1-AR in the endothelium in comparison to VSMC. 
However, there were no differences in the level of expression of β1-, β2- or β3-AR 
between WKY and SH rats.  
In the present study, SH animals had significantly higher central and peripheral 
(systolic and diastolic) blood pressures, pulse pressures and PWV than WKY rats at 
baseline. In addition, central pulse pressure was significantly different from peripheral 
pulse pressure in both WKY and SH rats. There was no significant difference in heart rate 
between WKY and SH rats.  
4.1 VSMC contribution to arterial stiffness  
In this investigation, the infusion of SNP (a NO donor) reduced PWV at all doses in 
SH rats, but not at any dose in WKY rats. Reduced PWV indicates increased vascular 
compliance, since the pulse travels quicker in stiffer arteries. These results provide clear 
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demonstration of the contribution of VSMC tone to arterial stiffness. The evidence seems 
to indicate that a reduction in arterial tone increases vascular compliance selectively in 
hypertension. As described further below, this is in agreement with studies that have 
altered vascular tone and have observed a change in arterial stiffness (Fitch et al., 2001; 
McVeigh et al., 2001; Wilkinson et al., 2002).  
Fitch and colleagues (2001) investigated the role of NO in vascular stiffness. Aortic 
PWV was measured after the administration of L-NAME (NOS inhibitor) or 
phenylephrine in Sprague-Dawley rats. In normal physiological conditions, the activation 
of eNOS generates NO by converting L-arginine to L-citrulline (Sessa et al., 1990). The 
administration of L-NAME would therefore limit the production of NO and NO-mediated 
vascular relaxation. Blood pressure and PWV (controlled for blood pressure changes) 
were reported to have increased significantly with the injection of L-NAME. At each 
level of mean arterial pressure, L-NAME also produced a greater increase in PWV than 
phenylephrine (Fitch et al., 2001). Similarly, the infusion of L-NMMA in normotensive 
individuals was associated with a dose-dependent increase of the augmentation index, an 
alternate measure of arterial stiffness (Wilkinson et al., 2002). The augmentation index is 
an indicator of the enhancement of the central blood pressure wave due to the extent of 
wave reflection off resistance sites and PWV, which determines the timing of the 
summation of the forward and backward pulse waves. Thus, these findings are an 
indicator that an increase in vascular tone can increase arterial stiffness by altering wave 
reflection. This evidence, in conjunction with our finding that SNP infusion reduces 
PWV in SH rats, supports the concept that VSMC relaxation can reduce PWV 
independently from blood pressure levels, and that this may be achieved with a NO 
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donor. This suggests that endothelial NO may also be able to reduce PWV by reducing 
aortic tone. Thus, further investigations conducted ex vivo could help confirm the 
specific roles of endogenous NO compared to exogenous NO (e.g. NO donors) on 
relaxation and arterial stiffness. Further studies could also help identify distinctions in 
vascular responses to endothelial-dependent dilators compared to endothelial-independent 
dilators (such as SNP).  
Other studies have also investigated the possibility that an alteration in vascular tone 
may have a linear relationship with PWV. Since direct blood pressure measurement in the 
aorta is considered invasive, many of these studies investigated arterial stiffness in other 
conduit vessels. It is therefore important to note that these studies need to be carefully 
scrutinized due to the differences in the mechanical properties of central arteries in 
comparison to peripheral arteries, such as differences in exposure to high systolic 
pressure or wave reflection (Bergel, 1960). The distinctions in the mechanical properties 
of peripheral and central arteries may have differing impacts on vascular compliance. 
Nonetheless, Kinlay and colleagues (2001) investigated arterial compliance in the 
brachial arteries of seven patients. An ultrasound catheter was used to measure vascular 
wall thickness, cross-sectional area and blood pressure. These measurements allowed for 
the calculation of circumferential wall stress, among other indices of stiffness. Stiffness 
was assessed after the administration of L-NMMA (to inhibit endothelium-derived NO), 
and after the administration of nitroglycerin (exogenous NO donor). L-NMMA infusion 
decreased compliance and PWV, while nitroglycerin increased compliance and PWV. 
Thus, endothelium-derived NO was reported to increase arterial compliance (Kinlay et 
al., 2001). As well, McEniery and colleagues (2003) examined the relationship between 
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ET-1 administration and PWV in the iliac artery of anesthetized sheep. The 
administration of ET-1 was accompanied by an increase in iliac PWV, while the infusion 
of an ET-1 antagonist was accompanied with a reduction in PWV. It is to be noted that 
this study had not controlled or corrected PWV for blood pressure. The incubation of 
carotid arteries with ET-1 antagonists (in vitro) also significantly increased vascular 
cross-sectional compliance (measured using a microscope connected to a video recorder) 
in both WKY and SH rats (Marano et al., 1999). In addition, high ET-1 levels in patients 
with renal failure and/or heart failure were associated with increased aortic PWV (not 
corrected for blood pressure), while the infusion of an ET-1 receptor blocker (VML-588) 
reduced PWV and the augmentation index (Vuurmans et al., 2003). Although the 
aforementioned investigations have examined other arteries, the evidence suggests that 
there is also a linear relationship between ET-1-mediated vascular tone and arterial 
stiffness. 
Furthermore, a reduction in vascular tone seems to reduce arterial stiffness in most 
conduit arteries. For example, Steppan and colleagues (2016) investigated the 
relationship between PWV and other metrics for arterial stiffness. Isoflurane-anesthetized 
Fisher and SH rats were infused with phenylephrine to achieve a central systolic blood 
pressure of 200 mmHg. The administration of phenylephrine was then stopped, and aortic 
PWV was measured as the blood pressure returned to normal. A nonlinear relationship 
between PWV and blood pressure (systolic, diastolic and MAP) was observed. The 
assumption was that changes in aortic PWV were due to alterations in vascular tone. 
However, a limitation to this study is that PWV was not measured at isobaric blood 
pressures, which makes it challenging to differentiate between the effects of blood 
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pressure on PWV and the effects of phenylephrine (or vasoconstriction). In addition, Fok 
and colleagues (2012) assessed PWV (using the Moens-Korteweg equation) between the 
human brachial and radial arteries in response to changes in vascular tone induced by 
different signaling pathways. The relationship between PWV and vascular tone was 
examined with the infusion of phentolamine alone, or in conjunction with nitroglycerin or 
norepinephrine in the brachial artery. Pearson correlation indicated a significant negative 
relationship between percent change in PWV and percent change in radial artery 
diameter, supporting the view that vascular tone is a contributing factor to vascular 
compliance. It is therefore likely that an increase in vascular tone may account for an 
increase in PWV, and vice-versa. 
In the current investigation, PWV was reduced in response to the administration of 
SNP or terbutaline in SH, but not in WKY rats. In this investigation, baseline blood 
pressures were lower in WKY than SH rats, and this could have contributed to the 
smaller reduction in blood pressures in WKY rats. It is also possible that WKY rats have 
reduced sensitivity to beta-agonists in comparison to SH rats, which could account for the 
lack of significant blood pressure reduction with the infusion of these drugs. Studies have 
shown that SH rats have increased vascular tone (Fitzpatrick and Szentivanyi, 1980), 
which may also account for the increased response to SNP in SH compared to WKY rats 
in the current investigation. The increased vascular tone in SH rats could also contribute 
to arterial stiffness by altering wave reflection and PWV (Shirwany and Zou, 2010). 
Greater VSMC stiffness in SH rats in comparison to WKY rats could also account for the 
lesser (non-significant) PWV reduction in WKY rats. A study by Sehgel and colleagues 
(2013) confirmed increased VSMC stiffness in SH rats in comparison to WKY rats by 
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using atomic force microscopy. It is also well known that SH rats have increased aortic 
wall thickness compared to WKY rats (Marque et al., 1999; Van Gorp et al., 1995), 
attributed to increased VSMC mass (Werstiuk and Lee, 2000), VSMC hyperploidy and 
polyploidy (Owens and Schwartz, 1982). It is therefore likely that the administration of 
SNP did not significantly decrease PWV in WKY rats due to the distinctions in the 
structure of blood vessels between SH and WKY rats. It is also probable that the ability to 
reduce PWV in compliant arteries is limited, since pulse transit time can only be reduced 
to a certain extent. In this investigation, β-AR agonists were also infused in WKY and SH 
rats to determine if the stimulation of β-AR has an impact on PWV.   
4.2 β-AR contribution to arterial stiffness  
It has been suggested that β-AR blockade may contribute to increased vascular 
stiffness due to impairment of relaxation of the conduit blood vessels, preventing the 
reduction of central aortic pressure (Klapholz, 2009; Dudenbostel and Glasser, 2012). 
However, evidence supporting this claim is scarce. In this investigation, the selective β2-
AR agonist terbutaline significantly decreased PWV in SH rats, but not in WKY rats. As 
discussed previously, the primary effect of β2-AR stimulation involves adrenergic-
mediated VSMC relaxation (Chruscinski et al., 2001). β2-AR stimulation has been 
reported to cause vascular relaxation of the rat aorta (O’Donnell and Wanstall, 1985). In 
fact, Kelly and colleagues (1989) reported that dilevalol (beta-blocker with β2-AR agonist 
properties) reduced PWV, wave reflection and the augmentation index in hypertensive 
patients (Kelly et al., 1989). β2-AR stimulation likely reduced PWV by reducing blood 
pressure and central vascular tone.  
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In the current investigation, the highest dose of terbutaline administered to SH rats 
did not significantly decrease PWV compared to their saline-infused time-control. It is 
possible that the sensitivity to the b2-agonist was reduced over time and with increasing 
doses, thereby decreasing the PWV effect seen at lower doses. It has been shown that 
beta-agonists tend to lose their selectivity at high concentrations (Baker, 2010). In 
addition, the administration of terbutaline significantly increased heart rate at the highest 
dose in SH rats, but not at any dose in WKY rats. The results of a study conducted by Tan 
and colleagues (2012) raise the possibility that the changes in heart rate may influence 
PWV results. In their study, they investigated the effects of heart rate on central PWV at 
various mean arterial pressures. Phenylephrine and SNP were infused to compare PWV at 
different blood pressures, and a bradycardic agent (zatebradine) was infused to reduce 
heart rate. Higher heart rates were found to be associated with an increase in PWV at all 
MAP greater than 80 mmHg, where the greatest change was 6.03±0.93% in the 110-130 
mmHg range (Tan et al., 2012). It is not possible to compare our data to that of Tan and 
colleagues, since they simultaneously altered heart rate and blood pressures. Nonetheless, 
it has been suggested that an increase in PWV observed with higher heart rates could be 
attributed to the increased exposure of blood vessels to systolic blood pressure, which 
causes distension of blood vessels and increased wave reflection (Wilkinson et al., 2000; 
Giannattasio et al., 2003). The highest doses of terbutaline and BRL37344 used in the 
current study both increased heart rate in SH rats, with PWV at similar levels. 
Furthermore, terbutaline decreased PWV at the lowest doses in SH rats, but BRL37344 
did not. It is possible that the increase in heart rate may have overshadowed the effect of 
the highest dose of terbutaline on PWV. It is also possible that BRL37344 did not 
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increase PWV at the highest dose for the reason that PWV was not altered at low doses 
and was already near its peak. Alternately, it is also possible that β 3-AR stimulation does 
not cause significant aortic relaxation, which could account for the reduction in PWV 
with terbutaline, but not BRL37344. Rodrigues and colleagues (2010) had shown that 
MMPs can cleave β2-AR in SH rats, which could minimize the function of β2-AR 
agonists in SH rats. However, this does not seem to be the case in the present study. The 
administration of terbutaline significantly decreased peripheral and central systolic blood 
pressures at all doses in SH rats, and at the highest dose in WKY rats. 
The administration of BRL37344, a selective β3-AR agonist, did not lower PWV in 
SH or WKY rats at any dose. However, BRL37344 infusion reduced central systolic and 
diastolic blood pressures in SH rats, and therefore mean central blood pressure, 
suggesting that it significantly reduced total peripheral resistance. It is possible that aortic 
vasodilation induced by BRL37344 was not sufficient to significantly reduce PWV, 
despite a reduction in blood pressure. It has been reported that BRL37344 produces a 
slow relaxation (5-8 min for peak response), (Oriowo, 1994) and has low efficacy and 
potency in VSMC of the thoracic aorta (Emorine et al., 1989; Brawley et al., 2000). 
Peripheral vasodilation has previously been observed in conscious rats infused with 
BRL37344 (Shen et al., 1996). However, Brawley and colleagues (2000) observed that 
the rat thoracic aorta dilation in response to BRL37344 was minimal in comparison to 
other atypical β-AR agonists. Thus, the stimulation of β3-AR by BRL37344 could have 
initiated peripheral vascular relaxation, with minimal relaxation in the central arteries. β3-
ARs also require higher concentrations of catecholamine to be stimulated than those 
required for β1- and β2-AR stimulation (Emorine et al., 1989). Therefore, it is possible 
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that BRL37344 elicited a reduction in total peripheral resistance and blood pressure, but 
with little or no alteration in the vascular tone of the aorta itself, resulting in no change in 
aortic PWV. The differences in central relaxation between β2- and β3-AR stimulation 
could account for the fact that there was PWV reduction with terbutaline, but not 
BRL37344 in SH rats.  
The effects of nebivolol (β1-blocker with NO donor) and atenolol (selective β1-
blocker) on PWV (not corrected for blood pressure) have previously been investigated in 
hypertensive patients (Mahmud and Feely, 2008). Both treatments reduced aortic PWV 
(nebivolol, 11.5 ± 0.5 to 9.9 ±0.5 m/s; atenolol, 11.1 ± 0.4 to 9.8 ± 0.4 m/s), however 
atenolol did not reduce wave reflection. A reduction in heart rate may explain the 
improved arterial distensibility associated with β1-AR blockade. Mahmud and Feely 
(2008) also suggested that the vasodilation caused by nebivolol could have contributed to 
the reduction in wave reflection. This is in agreement with a previous study in which the 
alterations in PWV in response to treatment with β-blockers (nebivolol or atenolol) were 
investigated. PWV and peripheral pulse pressure were significantly reduced from 
baseline at 2 and 10 weeks in all (hypertensive) treatment groups. Since nebivolol also 
significantly reduced the augmentation index, it was reported to be more effective in 
increasing arterial compliance in comparison to atenolol (Koumaras et al., 2014). The 
augmentation index was likely reduced with nebivolol due to its NO donor properties, 
which causes relaxation in the peripheral vasculature. Peripheral vasodilation leads to a 
reduction in total peripheral resistance, which reduces wave reflection. According to the 
evidence from investigations that have assessed the effect of β-blockers on arterial 
stiffness, the most efficient β-blockers in increasing vascular compliance and reducing 
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wave reflection seem to be selective β1-blockers (due to reduction in heart rate) and β-
blockers with NO donor properties (due to vascular relaxation).  
The infusion of isoprenaline (a β1- and β2-AR non-selective agonist) produced no 
significant change in PWV in WKY or SH rats despite a modest reduction in diastolic 
blood pressure in SH rats in the current study. It may be argued that the doses of 
isoprenaline administered in this investigation were too low to have an impact on PWV. 
The doses used in the present study were chosen (based on a pilot study) to be sufficient 
to reduce diastolic blood pressure, but low enough to avoid producing increases in heart 
rate. We avoided higher doses that increased heart rate since they would have had the 
potential to cause heart rate-mediated increase in arterial stiffness (Tan et al., 2012). 
Previous investigations have found that the minimal effective dose (determined by blood 
pressure, heart rate, among others) of isoprenaline was 0.003-0.01 µg/kg (Apperley et al., 
1976), while others have observed increased chronotropic responses at 0.04 and 0.01 
µg/kg/min in SH and WKY rats, respectively (Saragoca and Tarazi, 1981). Furthermore, 
isoprenaline infusions in the current investigation did cause a modest (insignificant) 
reduction in blood pressure, suggesting that it must have been close to the appropriate 
range of doses.  
Ultimately, the evidence suggests that β2-AR stimulation reduces arterial stiffness 
most likely due to the reduction in central vascular tone. In fact, β-AR agonists and 
antagonists can have a multitude of hemodynamic effects that can influence vascular 
stiffness. This topic will be covered in the following section.  
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4.3 Hemodynamics of the aorta 
In this investigation, peripheral pulse pressure was found to be significantly higher 
than central pulse pressure in both WKY and SH rats. Pulse pressure increases as it 
travels through the vasculature due to increasing vascular resistance in smaller arteries 
(Pauca et al., 1992), which increases wave reflection. Therefore, the difference between 
central and peripheral pulse pressure confirms that wave reflection is present in rodents, 
which is a characteristic of hemodynamic properties of the cardiovascular system also 
present in humans (Kelly et al., 1989; Koumaras et al., 2014).  
SNP is well established to induce vascular relaxation in the isolated rat aorta 
(Bonaventura et al., 2008; Fok et al., 2012). In our current investigation, SNP infusion 
reduced both central and peripheral pulse pressure in SH rats. Central and peripheral 
(systolic and diastolic) blood pressures were also reduced with the administration of SNP, 
suggesting that there was peripheral vasodilation. Yet, we are unsure as to whether the 
reduction in central pulse pressure was due to vasodilation of the central and/or peripheral 
vasculature. Nonetheless, the administration of SNP reduced PWV in SH rats, but 
BRL37344 did not, despite comparable levels of blood pressure at each dose. Therefore, 
it is likely that central blood vessels are the main protagonists in reducing aortic PWV.   
Drugs that reduce blood pressure such as the β-AR agonists and SNP used in this 
investigation may activate the baroreceptor reflex, leading to an activation of the SNS. 
The animals in this investigation were anesthetized with isoflurane, which is known to 
depress the baroreflex in normotensive and hypertensive rabbits (Bell, 1994), as well as 
in humans (Kotrly et al., 1984). SNP infusions did not increase heart rate despite large 
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reductions in blood pressure, suggesting that the baroreflex was indeed depressed, and 
unlikely to influence our results.   
We expected that the effect of drugs on central arterial stiffness (PWV) might have 
been evident with changes in the central arterial pulse pressure. However, central arterial 
pulse pressure does not appear to be a very reliable metric of arterial elasticity since there 
does not seem to be a clear relationship between PWV reduction and central (or 
peripheral) pulse pressure in the current investigation. This could be due to the alteration 
of PWV, heart rate and vascular resistance, which affect wave reflection and 
augmentation (important contributors to pulse pressure). Further, a selective β-AR 
agonist may lose its selectivity at higher doses, and stimulate other subtypes of β-AR 
(Baker, 2010). Therefore, the increase in heart rate at the highest dose of terbutaline and 
BRL37344 could be attributed to the loss of selectivity. In the present study, we also 
investigated β-AR expression in the abdominal aorta of WKY and SH rats to determine 
whether β-AR density could account for differences in arterial stiffness and/or 
hemodynamic responses to β-AR stimulation. 
4.4 Immunofluorescence 
In the current investigation, β3-AR expression in the abdominal aorta was 
investigated with immunofluorescence techniques. We have identified β3-AR expression 
in the endothelium, VSMCs, and in the adventitial tissue of the abdominal aorta of both 
WKY and SH rats. β3-AR was initially identified in adipocytes (Emorine et al., 1989; 
Ferrer-Lorente, 2005), and was subsequently identified in cardiomyocytes (Cohen et al., 
1999). In addition, β3-AR has been associated with NO-mediated vasodilation in human 
coronary microarteries (blood vessels that branch off from the coronary arteries) (Dessy 
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et al., 2004). Rautureau and colleagues (2002) also confirmed the presence of endothelial 
β3-AR in the rat thoracic aorta by immunohistochemistry techniques. The current 
investigation has also revealed β3-AR expression in VSMCs of the rat abdominal aorta.  
It has been shown that stimulation of β3-AR in the rat thoracic aorta causes 
relaxation, which is greatly reduced by an eNOS inhibitor (Trochu et al., 1999). This 
evidence suggests that β3-AR-activity is largely endothelium-dependent. The infusion of 
an NO donor such as SNP can initiate a strong relaxation of the entire vascular wall of the 
aorta, since the vasa vasorum (network of vessels responsible for supplying blood to the 
walls of the aorta) can distribute NO to the entire vascular wall. On the other hand, it is 
possible that endothelial NO (e.g. released β3-AR stimulation) is not capable of initiating 
relaxation of the entire aortic vascular wall. Further studies are needed to elucidate this 
idea.  
Conversely, vascular relaxation triggered by the stimulation of β1- and β2-AR has 
been linked to their presence in VSMCs. The evidence for β1- and β2-AR in the aortic 
endothelium is sparse. However, endothelial β1- and β2-AR-mediated relaxation has been 
reported in other blood vessels, but to a lesser extent than β1- and β2-AR located in 
VSMC (Oriowo, 1995; Brawley et al., 2000). In this investigation, β1- and β2-AR were 
found to be expressed in the endothelium and VSMCs of the abdominal aorta of both 
WKY and SH rats. These findings concur with evidence of β2-AR in VSMCs (Brodde 
and Michel, 1992; Takata and Kato 1996), and those concluding that the role of vascular 
β1- and β2-AR is relaxation (Chruscinski et al., 2001). Functional studies also suggested 
greater relaxation to β2-AR-stimulation than β1-AR stimulation in the rat carotid artery 
(Chiba and Tsukuda, 2001). Surprisingly, with quantification analysis, we found greater 
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expression of β1-AR in the endothelium in comparison to VSMCs of both WKY and SH 
rats. 
No differences in β1-, β2- or β3-AR expression were found between WKY and SH 
rats, despite a previous report of β3-AR upregulation in the endothelial layer of the 
thoracic aorta of SH rats with immunohistochemistry (Mallem et al., 2004). Differential 
levels of β-AR-mediated relaxation have previously been reported, in which the thoracic 
aorta showed greater relaxation compared to the abdominal aorta (Fleisch et al., 1970). 
Thus, it is possible that β3-AR-mediated relaxation is more prominent in the thoracic 
aorta than in the abdominal aorta.  
4.5 Limitations 
 This study has a number of limitations. Fluid-filled catheters were used rather than 
electronic pressure sensor devices that measure pressure at the tip of the catheters, which 
could have limited the accuracy of our assessment of pulse transit time and PWV. In 
addition, the present investigation was an acute study, and cannot predict the effect of 
chronic changes in β-AR activity on arterial stiffness.  
As previously discussed, it is recognized that the measurement of parameters such as 
PWV are influenced by changes in heart rate and blood pressure, among other factors. 
Thus, the complex dynamic nature of blood vessels could limit the accuracy of arterial 
stiffness measurements. Hence, most studies assessing arterial stiffness are usually 
carried out using isolated blood vessels. However, the major disadvantage of in vitro 
investigations is that the true hemodynamic effects of blood flow on the vascular wall are 
absent, and values obtained under such circumstances could miss a host of physiological 
parameters that continuously influence arterial stiffness. Likewise, the lack of perfect 
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control in measuring PWV at isobaric blood pressures during drug infusions could 
contribute to an overestimation of the differences observed in PWV between WKY and 
SH rats. 
4.6 Future studies 
The current investigation seems to support the hypothesis that vasodilation of the 
central arteries (e.g. with SNP) can have an important role in the reduction of stiffness in 
a state of hypertension. The findings also suggest that β2-AR stimulation may play a role 
in the alteration of vascular compliance, however it is not clear whether this effect would 
occur independently from aortic relaxation. Furthermore, we confirmed the expression of 
β3-AR in the abdominal aorta, and increased expression of β1-AR in the endothelium in 
comparison to VSMCs. These findings are important in understanding the mechanical 
properties of the central arteries in a state of high intravascular pressure.  
Further studies are required to establish the impact of long-term vascular relaxation 
on vascular compliance. It would also be interesting to investigate the effect of chronic 
treatment with selective β-blockers compared to β-blockers with NO donor properties on 
arterial stiffness in a state of hypertension. It has been suggested that β-AR blockade may 
contribute to increased vascular stiffness due to impairment of relaxation (Klapholz, 
2009; Dudenbostel and Glasser, 2012). However, evidence to support this claim is 
lacking, and the current literature on this subject suggests that selective β1-blockers and 
those with NO donor properties may in fact reduce arterial stiffness. Relaxation of the 
large central arteries seems to play an important role in increasing vascular compliance. 
Hence, future studies are needed in order to investigate the effects of selective β-blockers 
on arterial stiffness to provide insight on effective treatment options for hypertension.  
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 64	
5. References 
Ablad, B., Carlsson, B., Carlsson, E., Dahlof, C., Ek, L., & Hultberg, E. (1974). Cardiac 
effects of beta-adrenergic receptor antagonists. Advances in Cardiology, 12(0), 290-
302.  
 
Ahlquist, R. P. (1948). A study of the adrenotropic receptors. The American Journal of 
Physiology, 153(3), 586-600. 
 
Apperley, G. H., Daly, M. J., & Levy, G. P. (1976). Selectivity of beta-adrenoceptor 
agonists and antagonists on bronchial, skeletal, vascular and cardiac muscle in the 
anaesthetized cat. British Journal of Pharmacology, 57(2), 235–246. 
 
Baker, J. G. (2010). The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- 
and beta3-adrenoceptors. British Journal of Pharmacology, 160(5), 1048-1061. 
doi:10.1111/j.1476-5381.2010.00754.x [doi] 
 
Basalyga, D. M., Simionescu, D. T., Xiong, W., Baxter, B. T., Starcher, B. C., & 
Vyavahare, N. R. (2004). Elastin degradation and calcification in an abdominal aorta 
injury model: Role of matrix metalloproteinases. Circulation, 110(22), 3480-3487. 
doi:01.CIR.0000148367.08413.E9 [pii] 
 
Bell, L. B. (1994). Baroreflex modulation by isoflurane anesthesia in normotensive and 
chronically hypertensive rabbits. Advances in Pharmacology (San Diego, Calif.), 31, 
389-408. 
 
Belz, G. G. (1995). Elastic properties and windkessel function of the human aorta. 
Cardiovascular Drugs and Therapy / Sponsored by the International Society of 
Cardiovascular Pharmacotherapy, 9(1), 73-83. 
 
Bergel, D. H. (1961). The static elastic properties of the arterial wall. The Journal of 
Physiology, 156(3), 445-457. 
 
Bonaventura, D., Lunardi, C. N., Rodrigues, G. J., Neto, M. A., & Bendhack, L. M. 
(2008). A novel mechanism of vascular relaxation induced by sodium nitroprusside in 
the isolated rat aorta. Nitric Oxide : Biology and Chemistry, 18(4), 287-295. 
doi:10.1016/j.niox.2008.02.004 [doi] 
Boutouyrie, P., Fliser, D., Goldsmith, D., Covic, A., Wiecek, A., Ortiz, A., . . . London, 
G. M. (2014). Assessment of arterial stiffness for clinical and epidemiological studies: 
Methodological considerations for validation and entry into the european renal and 
cardiovascular medicine registry. Nephrology, Dialysis, Transplantation : Official 
Publication of the In vivo/in vitro comparison of rat abdominal aorta wall viscosity: 
influence of endothelial function European Dialysis and Transplant Association - 
European Renal Association, 29(2), 232-239.  
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 65	
Brandts, A., Westenberg, J. J., van Elderen, S. G., Kroft, L. J., Roes, S. D., Tamsma, J. 
T., . . . de Roos, A. (2013). Site-specific coupling between vascular wall thickness and 
function: An observational MRI study of vessel wall thickening and stiffening in 
hypertension. Investigative Radiology, 48(2), 86-91. 
doi:10.1097/RLI.0b013e31827f6410 [doi] 
Brawley, L., Shaw, A. M., & MacDonald, A. (2000). Beta 1-, beta 2- and atypical beta-
adrenoceptor-mediated relaxation in rat isolated aorta. British Journal of 
Pharmacology, 129(4), 637-644. doi:10.1038/sj.bjp.0703091 [doi]  
 
Bray, M. S., Krushkal, J., Li, L., Ferrell, R., Kardia, S., Sing, C. F., . . . Boerwinkle, E. 
(2000). Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as 
a susceptibility locus for human hypertension. Circulation, 101(25), 2877-2882. 
 
Brodde, O. E., & Michel, M. C. (1992). Adrenergic receptors and their signal 
transduction mechanisms in hypertension. Journal of Hypertension.Supplement : 
Official Journal of the International Society of Hypertension, 10(7), S133-45. 
 
Bulbring, E., & Tomita, T. (1987). Catecholamine action on smooth muscle. 
Pharmacological Reviews, 39(1), 49-96. 
 
Butlin, M., Lindesay, G., Viegas, K. D., & Avolio, A. P. (2015). Pressure dependency of 
aortic pulse wave velocity in vivo is not affected by vasoactive substances that alter 
aortic wall tension ex vivo. American Journal of Physiology.Heart and Circulatory 
Physiology, 308(10), H1221-8. doi:10.1152/ajpheart.00536.2014 [doi] 
 
Candelore, M. R., Deng, L., Tota, L., Guan, X. M., Amend, A., Liu, Y., . . . Weber, A. E. 
(1999). Potent and selective human beta(3)-adrenergic receptor antagonists. The 
Journal of Pharmacology and Experimental Therapeutics, 290(2), 649-655. 
 
Charkoudian, N., & Rabbitts, J. A. (2009). Sympathetic neural mechanisms in human 
cardiovascular health and disease. Mayo Clinic Proceedings, 84(9), 822-830. 
doi:10.1016/S0025-6196(11)60492-8 [doi] 
 
Cheng, J. B., & Shibata, S. (1981). Vascular relaxation in the spontaneously hypertensive 
rat. Journal of Cardiovascular Pharmacology, 3(5), 1126-1140. 
 
Chiba, S., & Tsukada, M. (2001). Vascular responses to beta-adrenoceptor subtype-
selective agonists with and without endothelium in rat common carotid 
arteries. Journal of Autonomic Pharmacology, 21(1), 7-13. doi:jap199 [pii] 
 
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. 
L.,Jr, . . . National High Blood Pressure Education Program Coordinating Committee. 
(2003). The seventh report of the joint national committee on prevention, detection, 
evaluation, and treatment of high blood pressure: The JNC 7 report. Jama, 289(19), 
2560-2572. doi:10.1001/jama.289.19.2560 [doi] 
 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 66	
Chruscinski, A., Brede, M. E., Meinel, L., Lohse, M. J., Kobilka, B. K., & Hein, L. 
(2001). Differential distribution of beta-adrenergic receptor subtypes in blood vessels 
of knockout mice lacking beta(1)- or beta(2)-adrenergic receptors. Molecular 
Pharmacology, 60(5), 955-962. 
 
Cohen, M. L., Bloomquist, W., Kriauciunas, A., Shuker, A., & Calligaro, D. (1999). Aryl 
propanolamines: Comparison of activity at human beta3 receptors, rat beta3 receptors 
and rat atrial receptors mediating tachycardia. British Journal of Pharmacology, 
126(4), 1018-1024. doi:10.1038/sj.bjp.0702364 [doi] 
 
Daneshtalab, N., Dore, J. J., & Smeda, J. S. (2010). Troubleshooting tissue specificity 
and antibody selection: Procedures in immunohistochemical studies. Journal of 
Pharmacological and Toxicological Methods, 61(2), 127-135. 
doi:10.1016/j.vascn.2009.12.002 [doi] 
 
Dao, H. H., Essalihi, R., Bouvet, C., & Moreau, P. (2005). Evolution and modulation of 
age-related medial elastocalcinosis: Impact on large artery stiffness and isolated 
systolic hypertension. Cardiovascular Research, 66(2), 307-317. doi:S0008-
6363(05)00040-4 [pii] 
 
Del Colle, S., Morello, F., Rabbia, F., Milan, A., Naso, D., Puglisi, E., . . . Veglio, F. 
(2007). Antihypertensive drugs and the sympathetic nervous system. Journal of 
Cardiovascular Pharmacology, 50(5), 487-496. doi:10.1097/FJC.0b013e318135446c 
[doi] 
 
Dessy, C., Moniotte, S., Ghisdal, P., Havaux, X., Noirhomme, P., & Balligand, J. L. 
(2004). Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary 
microarteries through nitric oxide and endothelium-dependent hyperpolarization. 
Circulation, 110(8), 948-954. doi:10.1161/01.CIR.0000139331.85766.AF [doi] 
 
Domanski, M. J., Davis, B. R., Pfeffer, M. A., Kastantin, M., & Mitchell, G. F. (1999). 
Isolated systolic hypertension : Prognostic information provided by pulse pressure. 
Hypertension (Dallas, Tex.: 1979), 34(3), 375-380. 
 
Dudenbostel, T., & Glasser, S. P. (2012). Effects of antihypertensive drugs on arterial 
stiffness. Cardiology in Review, 20(5), 259-263. doi:10.1097/CRD.0b013e31825d0a44 
[doi] 
 
Emorine, L. J., Marullo, S., Briend-Sutren, M. M., Patey, G., Tate, K., Delavier-
Klutchko, C., & Strosberg, A. D. (1989). Molecular characterization of the human beta 
3-adrenergic receptor. Science (New York, N.Y.), 245(4922), 1118-1121. 
 
Ferrer-Lorente, R., Cabot, C., Fernandez-Lopez, J. A., & Alemany, M. (2005). Combined 
effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of 
diet-induced overweight male wistar rats. Life Sciences, 77(16), 2051-2058. 
doi:S0024-3205(05)00412-1 [pii]  
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 67	
 
Fitch, R. M., Vergona, R., Sullivan, M. E., & Wang, Y. X. (2001). Nitric oxide synthase 
inhibition increases aortic stiffness measured by pulse wave velocity in 
rats. Cardiovascular Research, 51(2), 351-358. doi:S0008636301002991 [pii] 
 
Fitzpatrick, D. F., & Szentivanyi, A. (1980). The relationship between increased 
myogenic tone and hyporesponsiveness in vascular smooth muscle of spontaneously 
hypertensive rats. Clinical and Experimental Hypertension, 2(6), 1023-1037. 
 
Fleisch, J. H., Maling, H. M., & Brodie, B. B. (1970). Beta-receptor activity in aorta; 
variations with age and species. Circulation Research, 26(2), 151-162. 
 
Fok, H., Jiang, B., Clapp, B., & Chowienczyk, P. (2012). Regulation of vascular tone and 
pulse wave velocity in human muscular conduit arteries: Selective effects of nitric 
oxide donors to dilate muscular arteries relative to resistance vessels. Hypertension 
(Dallas, Tex.: 1979), 60(5), 1220-1225. 
doi:10.1161/HYPERTENSIONAHA.112.198788 [doi] 
 
Franklin, S. S., Gustin, W.,4th, Wong, N. D., Larson, M. G., Weber, M. A., Kannel, W. 
B., & Levy, D. (1997). Hemodynamic patterns of age-related changes in blood 
pressure. the framingham heart study. Circulation, 96(1), 308-315. 
 
Franklin, S. S., Khan, S. A., Wong, N. D., Larson, M. G., & Levy, D. (1999). Is pulse 
pressure useful in predicting risk for coronary heart disease? the framingham heart 
study. Circulation, 100(4), 354-360. 
 
Frishman, W. (1981). Beta-adrenoceptor antagonists: New drugs and new indications. 
New England Journal of Medicine, 305(9), 505-506. 
 
Frishman, W. (1984). Clinical pharmacology of the beta-adrenoceptor blocking drugs 
(2nd ed. ed.). Norwalk: Appleton-Century-Crofts. 
 
Gao, F., de Beer, V. J., Hoekstra, M., Xiao, C., Duncker, D. J., & Merkus, D. (2010). 
Both beta1- and beta2-adrenoceptors contribute to feedforward coronary resistance 
vessel dilation during exercise. American Journal of Physiology.Heart and 
Circulatory Physiology, 298(3), H921-9. doi:10.1152/ajpheart.00135.2009 [doi] 
 
Giannattasio, C., Vincenti, A., Failla, M., Capra, A., Ciro, A., De Ceglia, S., . . . Mancia, 
G. (2003). Effects of heart rate changes on arterial distensibility in 
humans. Hypertension (Dallas, Tex.: 1979), 42(3), 253-256. 
doi:10.1161/01.HYP.0000085199.33254.15 [doi] 
 
Girard, A., Meilhac, B., Mounier-Vehier, C., & Elghozi, J. L. (1995). Effects of beta-
adrenergic blockade on short-term variability of blood pressure and heart rate in 
essential hypertension. Clinical and Experimental Hypertension (New York, N.Y.: 
1993), 17(1-2), 15-27. 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 68	
 
Granneman, J. G. (2001). The putative beta4-adrenergic receptor is a novel state of the 
beta1-adrenergic receptor. American Journal of Physiology.Endocrinology and 
Metabolism, 280(2), E199-202. 
 
Guyenet, P. G. (2006). The sympathetic control of blood pressure. Nature 
Reviews.Neuroscience, 7(5), 335-346. doi:nrn1902 [pii] 
 
Guyton, A. C., & Hall, J. E. (2011). Textbook of medical physiology (10th ed. ed., pp. 
709). Philadelphia: W.B. Saunders Company. 
 
Haeusler, G. (1990). Pharmacology of beta-blockers: Classical aspects and recent 
developments. Journal of Cardiovascular Pharmacology, 16 Suppl 5, S1-9. 
 
Huveneers, S., Daemen, M. J., & Hordijk, P. L. (2015). Between rho(k) and a hard place: 
The relation between vessel wall stiffness, endothelial contractility, and cardiovascular 
disease. Circulation Research, 116(5), 895-908. 
doi:10.1161/CIRCRESAHA.116.305720 [doi] 
 
Institute of Laboratory Animal Resources. (1976). History of the spontaneously 
hypertensive rat. Spontaneously hypertensive (SHR) rats: Guidelines for breeding, 
care, and use (pp. G6-G7). Washington, D.C.: National Academies. 
 
Jacob M.P. (2003) Extracellular matrix remodeling and matrix metalloproteinases in the 
vascular wall during aging and in pathological conditions. Biomed. Pharmacother. 
57:195–202. 
 
Jaillon, P. (1990). Relevance of intrinsic sympathomimetic activity for beta blockers. The 
American Journal of Cardiology, 66(9), 21C-23C. 
 
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., 
Handler, J., . . . Ortiz, E. (2014). 2014 evidence-based guideline for the management 
of high blood pressure in adults: Report from the panel members appointed to the 
eighth joint national committee (JNC 8). Jama, 311(5), 507-520. 
doi:10.1001/jama.2013.284427 [doi] 
 
Joannides, R., Haefeli, W. E., Linder, L., Richard, V., Bakkali, E. H., Thuillez, C., & 
Luscher, T. F. (1995). Nitric oxide is responsible for flow-dependent dilatation of 
human peripheral conduit arteries in vivo. Circulation, 91(5), 1314-1319. 
 
Johansson, L. H. (1995). Factors behind the functional beta 2-adrenoceptor selectivity of 
terbutaline. Pharmacology & Toxicology, 77 Suppl 3, 21-24. 
 
Kaumann, A. J. (1989). Is there a third heart beta-adrenoceptor? Trends in 
Pharmacological Sciences, 10(8), 316-320. doi:0165-6147(89)90065-5 [pii] 
 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 69	
Kelly, R., Daley, J., Avolio, A., & O'Rourke, M. (1989). Arterial dilation and reduced 
wave reflection. benefit of dilevalol in hypertension. Hypertension (Dallas, Tex.: 
1979), 14(1), 14-21. 
 
Kinlay, S., Creager, M. A., Fukumoto, M., Hikita, H., Fang, J. C., Selwyn, A. P., & Ganz, 
P. (2001). Endothelium-derived nitric oxide regulates arterial elasticity in human 
arteries in vivo. Hypertension (Dallas, Tex.: 1979), 38(5), 1049-1053. 
 
Klapholz, M. (2009). Beta-blocker use for the stages of heart failure. Mayo Clinic 
Proceedings, 84(8), 718-729. doi:10.4065/84.8.718 [doi] 
 
Kotrly, K. J., Ebert, T. J., Vucins, E., Igler, F. O., Barney, J. A., & Kampine, J. P. (1984). 
Baroreceptor reflex control of heart rate during isoflurane anesthesia in 
humans. Anesthesiology, 60(3), 173-179. 
 
Koumaras, C., Tziomalos, K., Stavrinou, E., Katsiki, N., Athyros, V. G., Mikhailidis, D. 
P., & Karagiannis, A. (2014). Effects of renin-angiotensin-aldosterone system 
inhibitors and beta-blockers on markers of arterial stiffness. Journal of the American 
Society of Hypertension : JASH, 8(2), 74-82. doi:10.1016/j.jash.2013.09.001 [doi] 
 
Lands, A. M., Luduena, F. P., & Buzzo, H. J. (1967). Differentiation of receptors 
responsive to isoproterenol. Life Sciences, 6(21), 2241-2249. 
 
Laragh J. (2001) Laragh’s lessons in pathophysiology and clinical pearls for treating 
hypertension. American Journal of Hypertension. (14) 296-304.  
 
Laurent, S., Cockcroft, J., Van Bortel, L., Boutouyrie, P., Giannattasio, C., Hayoz, D., . . . 
European Network for Non-invasive Investigation of Large Arteries. (2006). Expert 
consensus document on arterial stiffness: Methodological issues and clinical 
applications. European Heart Journal, 27(21), 2588-2605. doi:ehl254 [pii] 
 
Lefkowitz, R. J. (2007). Seven transmembrane receptors: Something old, something new. 
Acta Physiologica (Oxford, England), 190(1), 9-19. doi:APS1693 [pii] 
 
Lehmann, E. D. (1999). Terminology for the definition of arterial elastic properties. 
Pathologie-Biologie, 47(6), 656-664.  
 
Leung, A. A., Daskalopoulou, S. S., Dasgupta, K., McBrien, K., Butalia, S., Zarnke, K. 
B., . . . Hypertension Canada. (2017). Hypertension canada's 2017 guidelines for 
diagnosis, risk assessment, prevention, and treatment of hypertension in adults. The 
Canadian Journal of Cardiology, 33(5), 557-576. doi:S0828-282X(17)30110-1 [pii] 
 
Lindholm, L. H., Carlberg, B., & Samuelsson, O. (2005). Should beta blockers remain 
first choice in the treatment of primary hypertension? A meta-analysis. Lancet 
(London, England), 366(9496), 1545-1553. doi:S0140-6736(05)67573-3 [pii] 
 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 70	
Lofdahl, C. G., Marlin, G. E., & Svedmyr, N. (1983). Pafenolol, a highly selective beta 1-
adrenoceptor-antagonist, in asthmatic patients: Interaction with terbutaline. Clinical 
Pharmacology and Therapeutics, 33(1), 1-9. doi:0009-9236(83)90557-X [pii] 
 
Lucini, D., Pagani, M., Mela, G. S., & Malliani, A. (1994). Sympathetic restraint of 
baroreflex control of heart period in normotensive and hypertensive subjects. Clinical 
Science (London, England : 1979), 86(5), 547-556. 
 
Mackenzie, I. S., Wilkinson, I. B., & Cockcroft, J. R. (2002). Assessment of arterial 
stiffness in clinical practice. QJM : Monthly Journal of the Association of Physicians, 
95(2), 67-74. 
 
Maffei, A., Vecchione, C., Aretini, A., Poulet, R., Bettarini, U., Gentile, M. T., . . . 
Lembo, G. (2006). Characterization of nitric oxide release by nebivolol and its 
metabolites. American Journal of Hypertension, 19(6), 579-586. doi:S0895-
7061(05)01198-2 [pii] 
 
Mahmud, A., & Feely, J. (2008). Beta-blockers reduce aortic stiffness in hypertension but 
nebivolol, not atenolol, reduces wave reflection. American Journal of 
Hypertension, 21(6), 663-667. doi:10.1038/ajh.2008.156 [doi] 
 
Mallem, M. Y., Toumaniantz, G., Serpillon, S., Gautier, F., Gogny, M., Desfontis, J. C., 
& Gauthier, C. (2004). Impairment of the low-affinity state beta1-adrenoceptor-
induced relaxation in spontaneously hypertensive rats. British Journal of 
Pharmacology, 143(5), 599-605. doi:sj.bjp.0705990 [pii] 
 
Marano, G., Grigioni, M., Palazzesi, S., & Ferrari, A. U. (1999). Endothelin and 
mechanical properties of the carotid artery in wistar-kyoto and spontaneously 
hypertensive rats. Cardiovascular Research, 41(3), 701-707. doi:S0008-
6363(98)00240-5 [pii] 
 
Marieb, E. N., & Hoehn, K. (2013). Human anatomy & physiology (9th ed. ed.). 
Glenview, IL: Pearson Education Inc. 
 
Marque, V., Kieffer, P., Atkinson, J., & Lartaud-Idjouadiene, I. (1999). Elastic properties 
and composition of the aortic wall in old spontaneously hypertensive rats. 
Hypertension (Dallas, Tex.: 1979), 34(3), 415-422. 
 
Marque, V., Van Essen, H., Struijker-Boudier, H. A., Atkinson, J., & Lartaud-
Idjouadiene, I. (2001). Determination of aortic elastic modulus by pulse wave velocity 
and wall tracking in a rat model of aortic stiffness. Journal of Vascular Research, 
38(6), 546-550.  
Matsushita, M., Tanaka, Y., & Koike, K. (2006). Studies on the mechanisms underlying 
beta-adrenoceptor-mediated relaxation of rat abdominal aorta. Journal of Smooth 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 71	
Muscle Research = Nihon Heikatsukin Gakkai Kikanshi, 42(6), 217-225. 
doi:JST.JSTAGE/jsmr/42.217 [pii] 
 
McEniery, C. M., Cockcroft, J. R., Roman, M. J., Franklin, S. S., & Wilkinson, I. B. 
(2014). Central blood pressure: current evidence and clinical importance. European 
Heart Journal, 35(26), 1719–1725.  
 
McEniery, C. M., Qasem, A., Schmitt, M., Avolio, A. P., Cockcroft, J. R., & Wilkinson, 
I. B. (2003). Endothelin-1 regulates arterial pulse wave velocity in vivo. Journal of the 
American College of Cardiology, 42(11), 1975-1981. doi:S0735109703012427 [pii] 
 
McEniery, C. M., Yasmin, Hall, I. R., Qasem, A., Wilkinson, I. B., Cockcroft, J. R., & 
ACCT Investigators. (2005). Normal vascular aging: Differential effects on wave 
reflection and aortic pulse wave velocity: The anglo-cardiff collaborative trial 
(ACCT). Journal of the American College of Cardiology, 46(9), 1753-1760. 
doi:S0735-1097(05)01781-X [pii] 
 
McVeigh, G. E., Allen, P. B., Morgan, D. R., Hanratty, C. G., & Silke, B. (2001). Nitric 
oxide modulation of blood vessel tone identified by arterial waveform 
analysis. Clinical Science (London, England : 1979), 100(4), 387-393. 
 
Milnor, W. R. (1989). Properties of the vascular wall. Hemodynamics (2nd ed., ). 
Baltimore: Williams & Wilkins. 
 
Mitchell, G.F., Pfeffer, M.A., Finn, P.V., Pfeffer, J.M. (1997). Comparison of techniques 
for measuring pulse-wave velocity in the rat. Journal of Applied Physiology (82) 203–
210.    
 
Morisco, C., Zebrowski, D. C., Vatner, D. E., Vatner, S. F., & Sadoshima, J. (2001). 
Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in 
the rat heart. Journal of Molecular and Cellular Cardiology, 33(3), 561-573. 
doi:10.1006/jmcc.2000.1332 [doi] 
 
Nichols WW, O'Rourke MF. McDonald's Blood Flow in Arteries: Theoretic, 
Experimental and Clinical Principles. 5th ed. London, England: Edward Arnold; 
2005. 
 
O’Donnell, S. R., & Wanstall, J. C. (1976). The contribution of extraneuronal uptake to 
the trachea-blood vessel selectivity of beta-adrenoceptor stimulants in vitro in guinea-
pigs. British Journal of Pharmacology, 57(3), 369–373. 
 
O'Donnell, S. R., & Wanstall, J. C. (1985). Responses to the beta 2-selective agonist 
procaterol of vascular and atrial preparations with different functional beta-
adrenoceptor populations. British Journal of Pharmacology, 84(1), 227-235. 
 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 72	
Okamoto, K., & Aoki, K. (1963). Development of a strain of spontaneously hypertensive 
rats. Japanese Circulation Journal, 27, 282-293. 
 
Oriowo, M. A. (1994). Atypical beta-adrenoceptors in the rat isolated common carotid 
artery. British Journal of Pharmacology, 113(3), 699-702. 
 
Oriowo, M. A. (1995). Different atypical beta-adrenoceptors mediate isoprenaline-
induced relaxation in vascular and non-vascular smooth muscles. Life 
Sciences, 56(15), PL269-75. doi:0024320595000763 [pii] 
 
Owens, G. K., & Schwartz, S. M. (1982). Alterations in vascular smooth muscle mass in 
the spontaneously hypertensive rat. role of cellular hypertrophy, hyperploidy, and 
hyperplasia. Circulation Research, 51(3), 280-289. 
 
Palombo, C., & Kozakova, M. (2016). Arterial stiffness, atherosclerosis and 
cardiovascular risk: Pathophysiologic mechanisms and emerging clinical 
indications. Vascular Pharmacology, 77, 1-7. doi:10.1016/j.vph.2015.11.083 [doi] 
 
Pauca, A. L., Wallenhaupt, S. L., Kon, N. D., & Tucker, W. Y. (1992). Does radial artery 
pressure accurately reflect aortic pressure? Chest, 102(4), 1193-1198. doi:S0012-
3692(16)34305-7 [pii] 
 
Pinterova, M., Kunes, J., & Zicha, J. (2011). Altered neural and vascular mechanisms in 
hypertension. Physiological Research / Academia Scientiarum Bohemoslovaca, 60(3), 
381-402. doi:932189 [pii] 
 
Quirke, V. (2006). Putting theory into practice: James black, receptor theory and the 
development of the beta-blockers at ICI, 1958-1978. Medical History, 50(1), 69-92. 
 
Rautureau, Y., Toumaniantz, G., Serpillon, S., Jourdon, P., Trochu, J. N., & Gauthier, C. 
(2002). Beta 3-adrenoceptor in rat aorta: Molecular and biochemical characterization 
and signalling pathway.British Journal of Pharmacology, 137(2), 153-161. 
doi:10.1038/sj.bjp.0704867 [doi] 
 
Reaven, P. D., Sacks, J., & Investigators for the Veterans Affairs Cooperative Study of 
Glycemic Control and Complications in Diabetes Mellitus Type 2. (2004). Reduced 
coronary artery and abdominal aortic calcification in hispanics with type 2 diabetes. 
Diabetes Care, 27(5), 1115-1120. 
 
Rettig, R. (1993). Does the kidney play a role in the aetiology of primary hypertension? 
evidence from renal transplantation studies in rats and humans. Journal of Human 
Hypertension, 7(2), 177-180. 
 
Rhodes, J. M., & Simons, M. (2007). The extracellular matrix and blood vessel 
formation: Not just a scaffold. Journal of Cellular and Molecular Medicine, 11(2), 
176-205. doi:JCMM031 [pii] 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 73	
Rodrigues, S. F., Tran, E. D., Fortes, Z. B., & Schmid-Schönbein, G. W. (2010). Matrix 
metalloproteinases cleave the β2-adrenergic receptor in spontaneously hypertensive 
rats. American Journal of Physiology - Heart and Circulatory Physiology, 299(1), 
H25–H35. 
 
Santulli, G., & Iaccarino, G. (2013). Pinpointing beta adrenergic receptor in ageing 
pathophysiology: Victim or executioner? evidence from crime scenes. Immunity & 
Ageing : I & A, 10(1), 10-4933-10-10. doi:10.1186/1742-4933-10-10 [doi] 
 
Saragoca, M., & Tarazi, R. C. (1981). Impaired cardiac contractile response to 
isoproterenol in the spontaneously hypertensive rat. Hypertension (Dallas, Tex.: 
1979), 3(3), 380-385. 
 
Sehgel, N. L., Zhu, Y., Sun, Z., Trzeciakowski, J. P., Hong, Z., Hunter, W. C., . . . 
Vatner, S. F. (2013). Increased vascular smooth muscle cell stiffness: A novel 
mechanism for aortic stiffness in hypertension. American Journal of Physiology.Heart 
and Circulatory Physiology, 305(9), H1281-7. doi:10.1152/ajpheart.00232.2013 [doi] 
 
Sessa, W. C., Hecker, M., Mitchell, J. A., & Vane, J. R. (1990). The metabolism of L-
arginine and its significance for the biosynthesis of endothelium-derived relaxing 
factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial 
cells. Proceedings of the National Academy of Sciences of the United States of 
America, 87(21), 8607-8611. 
 
Shadwick, R. E. (1999). Mechanical design in arteries. The Journal of Experimental 
Biology, 202(Pt 23), 3305-3313. 
 
Shafiei, M., & Mahmoudian, M. (1999). Atypical beta-adrenoceptors of rat thoracic 
aorta. General Pharmacology, 32(5), 557-562. doi:S0306362398002833 [pii] 
 
Shekhonin, B.V., Domogatsky, S.P., Idelson, G.L., Koteliansky, V.E., Rukosuev, V.S. 
(1987). Relative distribution of fibronectin and type I, III, IV, V collagens in normal 
and atherosclerotic intima of human arteries. Atherosclerosis. 67(1) 9-16.  
 
Shen, Y. T., Cervoni, P., Claus, T., & Vatner, S. F. (1996). Differences in beta 3-
adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. The 
Journal of Pharmacology and Experimental Therapeutics, 278(3), 1435-1443. 
 
Shirwany, N. A., & Zou, M. (2010). Arterial stiffness: a brief review. Acta 
Pharmacologica Sinica, 31(10), 1267–1276. http://doi.org/10.1038/aps.2010.123 
 
Steppan, J., Sikka, G., Hori, D., Nyhan, D., Berkowitz, D. E., Gottschalk, A., & Barodka, 
V. (2016). Seeking a blood pressure-independent measure of vascular 
properties. Hypertension Research : Official Journal of the Japanese Society of 
Hypertension, 39(1), 27-38. doi:10.1038/hr.2015.109 [doi] 
 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 74	
Takata, Y., & Kato, H. (1996). Adrenoceptors in SHR: Alterations in binding 
characteristics and intracellular signal transduction pathways. Life Sciences, 58(2), 91-
106. doi:0024320595022139 [pii] 
 
Tan, I., Butlin, M., Liu, Y. Y., Ng, K., & Avolio, A. P. (2012). Heart rate dependence of 
aortic pulse wave velocity at different arterial pressures in rats. Hypertension, 60(2), 
528-533. doi:10.1161/HYPERTENSIONAHA.112.194225 [doi] 
 
Toda, T., Tsuda, N., Nishimori, I., Leszczynski, D. E., & Kummerow, F. A. (1980). 
Morphometrical analysis of the aging process in human arteries and aorta. Acta 
Anatomica, 106(1), 35-44. 
 
Todd, M. E., Laye, C. G., & Osborne, D. N. (1983). The dimensional characteristics of 
smooth muscle in rat blood vessels. A computer-assisted analysis. Circulation 
Research, 53(3), 319-331. 
 
Trochu, J. N., Leblais, V., Rautureau, Y., Beverelli, F., Le Marec, H., Berdeaux, A., & 
Gauthier, C. (1999). Beta 3-adrenoceptor stimulation induces vasorelaxation mediated 
essentially by endothelium-derived nitric oxide in rat thoracic aorta. British Journal of 
Pharmacology, 128(1), 69-76. doi:10.1038/sj.bjp.0702797 [doi] 
 
Van Gorp, A. W., van Ingen Schenau, D. S., Hoeks, A. P., Struijker Boudier, H. A., 
Reneman, R. S., & De Mey, J. G. (1995). Aortic wall properties in normotensive and 
hypertensive rats of various ages in vivo. Hypertension (Dallas, Tex.: 1979), 26(2), 
363-368. 
 
Vulliemoz, Y., Verosky, M., & Triner, L. (1975). Effect of albuterol and terbutaline, 
synthetic beta adrenergic stimulants, on the cyclic 3',5'-adenosine monophosphate 
system in smooth muscle.The Journal of Pharmacology and Experimental 
Therapeutics, 195(3), 549-556. 
 
Vuurmans, T. J., Boer, P., & Koomans, H. A. (2003). Effects of endothelin-1 and 
endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave 
velocity in humans. Hypertension (Dallas, Tex.: 1979), 41(6), 1253-1258. 
doi:10.1161/01.HYP.0000072982.70666.E8 [doi] 
 
Wallace, S. M., Yasmin, McEniery, C. M., Maki-Petaja, K. M., Booth, A. D., Cockcroft, 
J. R., & Wilkinson, I. B. (2007). Isolated systolic hypertension is characterized by 
increased aortic stiffness and endothelial dysfunction. Hypertension (Dallas, Tex.: 
1979), 50(1), 228-233. doi:HYPERTENSIONAHA.107.089391 [pii] 
 
Wang, M., Takagi, G., Asai, K., Resuello, R. G., Natividad, F. F., Vatner, D. E., . . . 
Lakatta, E. G. (2003). Aging increases aortic MMP-2 activity and angiotensin II in 
nonhuman primates. Hypertension (Dallas, Tex.: 1979), 41(6), 1308-1316. 
doi:10.1161/01.HYP.0000073843.56046.45 [doi]  
 
ALTERATION IN VASCULAR FUNCTION DUE TO HIGH INTRAVASCULAR PRESSURE			
	 75	
Werstiuk, E. S., & Lee, R. M. (2000). Vascular beta-adrenoceptor function in 
hypertension and in ageing. Canadian Journal of Physiology and Pharmacology, 
78(6), 433-452. 
 
Wilkinson, I. B., MacCallum, H., Flint, L., Cockcroft, J. R., Newby, D. E., & Webb, D. J. 
(2000). The influence of heart rate on augmentation index and central arterial pressure 
in humans. The Journal of Physiology, 525 Pt 1, 263-270. doi:PHY_0449 [pii] 
 
Wilkinson, I. B., MacCallum, H., Cockcroft, J. R., & Webb, D. J. (2002). Inhibition of 
basal nitric oxide synthesis increases aortic augmentation index and pulse wave 
velocity in vivo. British Journal of Clinical Pharmacology, 53(2), 189-192. 
doi:1528a.doc [pii] 
 
Williams, B., Lacy, P. S., Thom, S. M., Cruickshank, K., Stanton, A., Collier, D., . . . 
CAFE Steering Committee and Writing Committee. (2006). Differential impact of 
blood pressure-lowering drugs on central aortic pressure and clinical outcomes: 
Principal results of the conduit artery function evaluation (CAFE) 
study. Circulation, 113(9), 1213-1225. doi:CIRCULATIONAHA.105.595496 [pii] 
 
Wolinsky, H., & Glagov, S. (1969). Comparison of abdominal and thoracic aortic medial 
structure in mammals. deviation of man from the usual pattern. Circulation Research, 
25(6), 677-686. 
 
Zieman, S. J., Melenovsky, V., & Kass, D. A. (2005). Mechanisms, pathophysiology, and 
therapy of arterial stiffness. Arteriosclerosis, Thrombosis, and Vascular Biology, 
25(5), 932-943. doi:01.ATV.0000160548.78317.29 [pii] 
 
 
 
 
 
 
 
 
 
